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Résumé 
Le papier bioactif est obtenu par la modification de substrat du papier avec des 
biomolécules et des réactifs. Ce type de papier est utilisé dans le développement de nouveaux 
biocapteurs qui sont portables, jetables et économiques visant à capturer, détecter et dans 
certains cas, désactiver les agents pathogènes. Généralement les papiers bioactifs sont fabriqués 
par l’incorporation de biomolécules telles que les enzymes et les anticorps sur la surface du 
papier. L’immobilisation de ces biomolécules sur les surfaces solides est largement utilisée pour 
différentes applications de diagnostic comme dans immunocapteurs et immunoessais mais en 
raison de la nature sensible des enzymes, leur intégration au papier à grande échelle a rencontré 
plusieurs difficultés surtout dans les conditions industrielles. Pendant ce temps, les 
microcapsules sont une plate-forme intéressante pour l’immobilisation des enzymes et aussi 
assez efficace pour permettre à la fonctionnalisation du papier à grande échelle car le papier 
peut être facilement recouvert avec une couche de telles microcapsules. 
Dans cette étude, nous avons développé une plate-forme générique utilisant des 
microcapsules à base d’alginate qui peuvent être appliquées aux procédés usuels de production 
de papier bioactif et antibactérien avec la capacité de capturer des pathogènes à sa surface et de 
les désactiver grâce à la production d’un réactif anti-pathogène. La conception de cette plate-
forme antibactérienne est basée sur la production constante de peroxyde d’hydrogène en tant 
qu’agent antibactérien à l’intérieur des microcapsules d’alginate. Cette production de peroxyde 
d’hydrogène est obtenue par oxydation du glucose catalysée par la glucose oxydase encapsulée 
à l’intérieur des billes d’alginate. Les différentes étapes de cette étude comprennent le piégeage 
de la glucose oxydase à l’intérieur des microcapsules d’alginate, l’activation et le renforcement  
de la surface des microcapsules par ajout d’une couche supplémentaire de chitosan, la 
vérification de la possibilité d’immobilisation des anticorps (immunoglobulines G humaine 
comme une modèle d’anticorps) sur la surface des microcapsules et enfin, l’évaluation des 
propriétés antibactériennes de cette plate-forme vis-à-vis l’Escherichia coli K-12 (E. coli K-12) 
en tant qu’un représentant des agents pathogènes. Après avoir effectué chaque étape, certaines 
mesures et observations ont été faites en utilisant diverses méthodes et techniques analytiques 
telles que la méthode de Bradford pour dosage des protéines, l’électroanalyse d’oxygène, la 
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microscopie optique et confocale à balayage laser (CLSM), la spectrométrie de masse avec 
désorption laser assistée par matrice- temps de vol (MALDI-TOF-MS), etc. Les essais 
appropriés ont été effectués pour valider la réussite de modification des microcapsules et pour 
confirmer à ce fait que la glucose oxydase est toujours active après chaque étape de 
modification. L’activité enzymatique spécifique de la glucose oxydase après l’encapsulation a 
été évaluée à 120±30 U/g. Aussi, des efforts ont été faits pour immobiliser la glucose oxydase 
sur des nanoparticules d’or avec deux tailles différentes de diamètre (10,9 nm et 50 nm) afin 
d’améliorer l’activité enzymatique et augmenter l’efficacité d’encapsulation. 
Les résultats obtenus lors de cette étude démontrent les modifications réussies sur les 
microcapsules d’alginate et aussi une réponse favorable de cette plate-forme antibactérienne 
concernant la désactivation de E. coli K-12. La concentration efficace de l’activité enzymatique 
afin de désactivation de cet agent pathogénique modèle a été déterminée à 1.3×10-2 U/ml pour 
une concentration de 6.7×108 cellules/ml de bactéries. D’autres études sont nécessaires pour 
évaluer l’efficacité de l’anticorps immobilisé dans la désactivation des agents pathogènes et 
également intégrer la plate-forme sur le papier et valider l’efficacité du système une fois qu’il 
est déposé sur papier.  
 
Mots-clés: Papier antibactérien / Encapsulation de la glucose oxydase / Microcapsules 
d’alginate / Inhibition de croissance de E. coli  
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Abstract 
Bioactive paper is obtained through the modification of paper substrate with biomolecules 
and reagents. It is used in the development of novel biosensors that are portable, disposable and 
inexpensive, aimed at capturing, detecting and in some cases deactivating pathogens. Generally 
bioactive papers are made by incorporating biomolecules such as enzymes and/or antibodies on 
to paper. The immobilization of such biomolecules on solid surfaces is widely used for different 
diagnostic applications such as in immunosensors and immunoassays but due to the sensitive 
nature of enzymes, their large scale incorporation into paper has faced several difficulties 
especially under industrial papermaking conditions. The functionalization of paper at large scale 
is possible because paper can be easily coated with a layer of microcapsules, which have proven 
to be an efficient immobilization platform for enzymes and to allow. 
In this study, we developed a generic alginate-based platform incorporating microcapsules 
that can be applied to current paper production processes to prepare antibacterial bioactive paper 
with the ability to capture pathogens on its surface and to deactivate them by producing an anti-
pathogenic agent. The design of the antibacterial platform is based on constant production of 
hydrogen peroxide as the antibacterial agent inside the alginate microcapsules. Hydrogen 
peroxide production is achieved through oxidation of glucose, catalyzed by the enzyme glucose 
oxidase encapsulated inside the alginate beads. The different steps of development included the 
entrapment of glucose oxidase inside alginate microcapsules, the reinforcement and surface 
activation of microcapsules by adding an additional layer of chitosan, investigating the 
possibility of immobilization of antibodies (human immunoglobulin G as a model antibody) on 
the surface of microcapsules and, finally, verifying the antibacterial properties of the system 
against Escherichia coli K-12 (E. coli K-12) as a representative pathogen. During development, 
certain measurements and observations were made using various analytical methods and 
techniques such as Bradford protein assay, oxygen electroanalysis, optical and confocal laser 
canning microscopy (CLSM), matrix assisted laser desorption/ionization- time of flight mass 
spectrometry (MALDI-TOF-MS), etc. Appropriate tests were performed to validate the 
successful modification of microcapsules and to ensure that glucose oxidase is still active after 
each modification. It was found that the encapsulated glucose oxidase maintained the specific 
enzymatic activity of 120±30 U/g. Subsequent efforts were made to immobilize glucose oxidase 
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on gold NPs of two different diameters (10.9 nm and 50 nm) to enhance the enzymatic activity 
and increase the encapsulation efficiency.   
The results obtained during this study demonstrate successful modifications on alginate 
microcapsules and also a successful response of such antibacterial platform regarding 
deactivation of the pathogen representative, E. coli K-12. The threshold for the enzymatic 
activity was found to be 1.3×10-2 U/ml for E. coli K-12 growth inhibition of 6.7×108 cells/ml. 
Further studies are needed to assess the efficiency of immobilized antibody in the capture of 
pathogens and also to incorporate the platform onto paper and to validate the efficiency of the 
system once it is coated on paper. 
 
Keywords: Antibacterial paper/ Glucose oxidase encapsulation/ Alginate microcapsules/ E. coli 
growth inhibition 
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Chapter 1. Introduction 
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1.1. Project design and objectives 
The objective of the project, as a part of Canada’s SENTINEL Bioactive Paper Network, 
is to develop a generic platform that can be applied to current paper production processes to 
prepare antibacterial bioactive paper that has the ability to capture pathogens on its surface and 
to deactivate them by producing an anti-pathogenic agent. As schematically demonstrated in 
Figure 1, this platform is based on alginate microcapsules carrying an active enzyme, glucose 
oxidase (GOx). While the enzyme is active inside microcapsules, in the presence of the substrate 
(glucose), a constant production of hydrogen peroxide occurs which can be used as an anti-
pathogenic agent. The pathogen capturing agent is an antibody specific to a given pathogen. The 
antibody needs to be covalently conjugated to the external surface of microcapsules to be able 
to capture the pathogens and with the production of hydrogen peroxide diffusing out of 
microcapsules, the pathogens are decomposed and therefore deactivated. The proposed 
microcapsule-based platform (which carries the enzymes inside and the antibody on its surface) 
will possess antibacterial properties and can be applied easily to industrial conventional paper 
production processes, either by coating the paper or by incorporating it into the paper pulp. 
Figure 1. Schematic view of the proposed antibacterial platform. 
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The specific steps in this project are as follows and the activity of the enzyme was 
measured after each step to evaluate possible losses; 
- Encapsulation of GOx in alginate microcapsules to prepare an enzymatically active 
platform. 
- Surface preparation and functionalization of alginate microcapsules using chitosan to 
add –NH2 functional groups on microcapsules. 
- Immobilization of IgG on the external surface of the alginate-chitosan microcapsules. 
- Testing the bacterial growth in the presence of the prepared system to verify its 
antibacterial properties and to determine the optimal conditions and the durability of the 
system. 
- GOx was immobilized on gold nanoparticles (NPs) and the effect of this immobilization 
on enzymatic activity was studied. 
1.2. Bioactive papers 
In modern times, mankind’s wellbeing is subject to various biological threats. 
Susceptibility against severe acute respiratory syndrome (SARS), water quality problems and 
incidents of tainted beef, for instance, underscore our vulnerability to biological hazards which 
is why we, as everyday water and food consumers, demand a safe and hygienic intake. Providing 
reliable food products and safety of the citizens have always been a concern for food production 
companies and regulatory authorities. To achieve such goals, paper-based sterile packaging, 
food wrap, face masks and protective clothing have been produced employing novel 
technologies and playing an important role in protecting us from pathogens1. 
Bioactive paper is a broad term used to define paper-based, portable, disposable and 
inexpensive biosensors aimed at capturing, detecting and in some cases deactivating pathogens. 
The research on bioactive paper is quite multidisciplinary as it lies at the interface of 
bioanalytical chemistry, paper chemistry and nanobiotechnology2. The history of bioactive 
paper dates back to 1952 when Martin and Syne won the Noble Prize in chemistry for the 
invention of paper chromatography3. Then in 1957, for the first time a paper-based bio assay 
was introduced by Free et al.4 for detection of glucose in urine samples. This paper based bio 
4 
 
assay was made by the incorporation of an enzyme, GOx, using a simple dipping procedure. 
Work has also been done to prepare a bacteria-based biosensor to detect low amounts of arsenic 
in potable water5. The color change in such biosensors indicated the presence of arsenic and it 
is visually detectable. The application then spread to Point-Of-Care (POC) tests, some quick and 
easy to do clinical tests which are used to diagnose diabetes, pregnancy and the presence of 
pathogens and infectious diseases such as AIDS, Malaria and Syphilis6. The incorporation of 
single-walled carbon nanotubes (SWNTs) and antibodies on to paper was described by Wang et 
al.7 to detect a water contaminant, microcystin-LR (MC-LR). Dip-coating of a strip of paper 
with carbon nanotubes and the antibody to MC-LR renders it conductive, and the change in 
conductivity of the paper strip was correlated to the presence of MC-LR in water samples. The 
possibility of printing antibodies on paper strips for blood type determination was demonstrated 
by Khan et al.8 and developed for inexpensive and portable blood-typing purposes. Savolainen 
et al.9 fabricated bioactive papers using three techniques, namely screen printing, rod coating, 
and flexo-printing. These methods were used to coat a paper with polyethylene (PE) 
microcapsules containing laccase. This bioactive paper, which contains laccase, was further 
improved by Virtanen et al10. Yu et al.11 have also designed a microfluidic paper-based 
chemiluminescence analytical device (μPCAD) for simultaneous detection of glucose and uric 
acid in urine samples. This lab-on-paper biosensor implements some enzymatically catalyzed 
oxidation reactions (GOx and urate oxidase) as well as the chemiluminescence reaction between 
a rhodanine derivative and generated hydrogen peroxide. In recent years some bioactive paper 
strips were invented for rapid detection of pathogens like E. coli based on intracellular enzyme 
(β-galactosidase or β-glucuronidase) activity12. Similarly, for rapid self-diagnosis of bacterial 
vaginosis Zhang and Rochefort13 developed an effective paper-based spot assay technique 
emphasizing its fast response and long-term storage stability. At the same time, some sensing 
platforms were designed for detection of phenols14 and pesticides15,16 which can potentially be 
used in the preparation of paper-based sensors. Another platform based on gold NPs, suitable 
for point-of-care applications, was developed to detect food-borne pathogens based on sensing 
of RNA markers17. 
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1.2.1. Functionality 
Certain advantages are found in using paper instead of plastic to prepare a bioactive 
surface. Biodegradability is an important characteristic of paper since it is made from naturally 
abundant cellulose and also it is more energy efficient. Its cellulosic structure is proven to be 
more compatible with proteins and biomolecules. The porous structure of paper facilitates a 
lateral flow assay and plays both roles of filtering and pumping by capillary forces and therefore, 
even in more complex paper-based microfluidic devices, there is no need to use an external 
power source to exert an interaction between the sample and the bioactive agent immobilized 
on the paper. Moreover, such paper substrates are inexpensive so they can be used to decrease 
the cost of diagnostic devices that are handy for on-site detection and can easily get to market 
since they are a proven technology to control the bacterial contamination in food samples.2 
1.3. Immobilization of biomolecules on paper 
There are certain structural and surface chemical properties of paper that affect the 
immobilization of biomolecules. Structural properties such as the porosity, mass distribution, 
the degree of crystallinity of fibers, their preferred orientation and accessible area of paper for 
immobilization influence the maximum quantity of biomolecules that can be immobilized.  
Surface chemical properties of paper such as the surface energy, surface sizing additives, 
cellulose grafting additives and plasma treatments of paper surface are factors that influence the 
facility of biomolecule immobilization and the reporting strategies2. Functionalization of paper 
is feasible either during the paper making process or on the finished paper. The goal in 
biomolecule immobilization on paper is to retain active biomolecules with maximal density and 
minimal leaching. In general, there are four methods available for this purpose: physical 
immobilization, covalent and affinity-based attachment, immobilization on carriers and 
entrapment18. 
1.3.1. Physical immobilization 
 In the physical immobilization method, the biomolecule adheres to the surface of the 
paper spontaneously via van der Waals and electrostatic interactions. This method is extensively 
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used in contact printing or non-contact paper printing (i.e. inkjet printing). These interactions 
can be improved by pre-coating of paper with cationic polymers, which graft well onto cellulose 
and render the surface highly cationic. Or in cases of neutral biomolecules, pre-coatings with a 
layer of hydrophobic molecules will enhance such interactions19. One of the potential problems 
of this method arises in certain cases of biomolecules that are not highly cationic thus their 
interaction with the paper surface (which is weakly anionic) is rather weak and results in the 
leaching of those biomolecules during assays in which the ionic strength of the media is high or 
the pH values are above 7. Another challenge would be the orientation of adhered biomolecules, 
which is essential to maintain their bioactivity. For instance, in the case of immobilizing 
bacteriophages on paper, a polyvinylamine pre-coating is required to render the surface of the 
paper positively charged so that the bacteriophage’s head (with a net negative charge) can be 
attached to the paper surface while the tail (with a net positive charge) remains still active to 
interact with the bacteria20. One drawback in using such modifications to increase electrostatic 
or hydrophobic interactions is that there is a high chance of encountering some non-specific 
binding onto paper which can be reduced by using blocking agents such as Tween 20 surfactant 
or bovine serum albumin (BSA) after the adsorption of the species of interest, but adding another 
step to the manufacturing process can be costly and in some cases difficult21.  
1.3.2. Covalent and affinity-based attachment 
In this approach a direct covalent bond acts as a bridge between biomolecules and paper. 
Since cellulose does not contain a significant chemically active group on its structure, some 
chemical modifications are needed to activate the surface of paper. These chemical 
modifications usually involve multiple steps, which adds to the manufacturing cost of the final 
product. One of the proposed solutions to resolve such difficulty is to fuse a cellulose-binding 
module (CBM) – generally a protein– to the biomolecule and then immobilize the biomolecule 
via such CBMs which attach to cellulose spontaneously. But seemingly, to synthesize such 
CBMs requires extra protein engineering which limits the versatility in large scale productions.18 
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1.3.3. Immobilization on carriers  
In the method using carriers, the biomolecules are first attached to a carrier molecule 
which is then printed onto paper surface. For instance, it was demonstrated that antibodies and 
DNA aptamers can be covalently attached to carboxylic poly(N-isopropylacrylamide) microgels 
and then printed on paper stripes to be used for paper chromatography22. The microgels are 
mechanically entrapped on paper and those biomolecules retain their recognition capabilities. 
After applying the microgels on paper strips it is necessary to let them dry before rewetting the 
paper. The drying will force the microgels to penetrate the fiber network of the paper as a result 
of capillary forces22. Using water-soluble carriers provides the possibility to incorporate them 
into water-based inks, but this method still suffers from the added complexity to the 
manufacturing process18.  
1.3.4. Entrapment 
Entrapment of biomolecules is carried out by entangling them in a network of cross linked 
polymers through a sol-gel process while maintaining the activity of the biomolecule. This 
network should be tight enough to prevent the leaching of biomolecules and at the same time it 
has to be porous enough to let smaller molecules such as reactants, substrates and target species 
pass through the gel and have access to active sites of biomolecules. Among all polymers, sol-
gel based silica and alginate-silica sol-gel hybrid are the most popular matrices for entrapment 
of biomolecules.23  
Encapsulation of biomolecules and microorganisms is another type of entrapment. In fact, 
this general term refers to a class of technologies which forms a polymeric matrix or shell around 
solids, liquids or gases, which traps them inside. The formation of encapsulated species is 
usually done is a single step and the particle size that is created using the encapsulation technique 
usually ranges from 1µm to 1000 µm; therefore, the particles are called “microcapsules” and the 
process is termed “microencapsulation”. Microcapsules have extensive applications as drug 
delivery systems in pharmaceutical and medical technology to protect the drug from 
environmental adverse effects, to eliminate incompatibilities, to stabilize sensitive drugs and 
also to mask their bad taste24. Apart from medical and pharmaceutical industries, microcapsules 
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have vast applications in other fields like in cosmetics, electronics, waste treatments, detergents, 
photography, graphics and paint industry, agriculture and food industry, etc25. 
1.4. Enzyme encapsulation 
As mentioned in Section 1.3, the biomolecule should maintain a high activity after the 
immobilization process. In the case of enzyme encapsulation, often the enzymatic activity is 
reduced during the encapsulation process26 (i.e. once it is trapped inside a microcapsule). There 
could be losses in enzyme quantity during the encapsulation process. Also, the heterogeneous 
confined space inside a microcapsule imposes some conformational changes in the structure of 
the enzyme resulting from interactions between the protein and the cross linked polymeric 
network of the microcapsule. These interactions, such as Lifshitz-van der Waals forces, dipolar 
or hydrogen bonding, conformational entropy, electrostatic forces, coulomb and hydrophobic 
dehydrations may stabilize certain conformations of the enzyme that are not favorable for the 
enzymatic activity. Also the diffusion rate of the substrate and other reactants across the 
microcapsules’ wall, which is controlled by the porosity, is a limiting factor for enzymatic 
activity because it reduces the access of the substrates to the enzyme’s active site26. However, 
in a very few reported cases, researchers were able to maintain the enzymatic activity. As 
demonstrated by Montalvo-Ortiz et al.27 the use of hydrogen peroxidase (HRP) NPs instead of 
a lyophilized protein formulation encapsulated in poly(lactic-co-glycolic) acid (PLGA) 
microspheres through the standard water-in-oil-in- water (w/o/w) methods, will enhance the 
encapsulation efficiency as well as reducing burst release and enhancing the enzymatic activity 
during release from PLGA microspheres.  
In recent years, biopolymers such as polysaccharides, proteins and lipids have been widely 
used as the matrix of microcapsules in microencapsulation process. There are five criteria that 
limit our choice of biopolymers for a given application: being a natural emulsifier for proteins 
and lipids, permeability for gases, the chemical composition and existing functional groups, the 
possibility of surface modification and finally its large scale availability in market with a 
reasonable price. A combination of all these criteria allows us to choose a compatible 
biopolymer for a certain application by granting them favorable properties such as mechanical 
9 
 
stability for storage, elasticity, biocompatibility, biodegradability and non-toxicity, etc28. A list 
of such biopolymers conventionally used as the matrix of microcapsules is given in Table 1. 
Table 1. Commonly used biopolymers in microencapsulation process (reproduced from 
reference 28).  
1.4.1.  Alginate-chitosan microcapsules 
Among all biopolymers commonly employed as the membrane material and the matrix 
for encapsulation, alginate is the most conventional and successful one because of its 
biocompatibility. It is also common to cover negatively charged polyamino acid polylysine 
microcapsules with an extra layer of alginate in order to improve biocompatibility of such 
membranes29. Alginate is the anion of alginic acid, which is a linear copolymer of β-D-
mannuronic acid (M) and α-L-guluronic acid (G) covalently linked together in different 
sequences or blocks. The M and G monomers are arranged in the alginate chain, to form three 
different sequences namely M-block (two M monomers attached together), G-block (two G 
monomers attached together) and alternating GM-block (a G monomer and an M monomer 
attached to each other). These different blocks composing the alginate linear body are illustrated 
in Figure 2. This anionic biopolymer is extensively found in cell walls of brown algae.30  
Divalent cations, such as calcium can crosslink alginate chains to form an “egg box model” 
structure. The formation of such structures is a result of an interaction between the divalent 
cation and the G-blocks of alginate, which creates a gel network (Figure 3)31,32. The ratio 
Source Polysaccharide-based Protein-based Lipid-based 
Plants 
Starch, 
Cyclodextrine, 
Pectine, etc. 
Gluten, 
Protein extracts from green 
beans, soy beans, lupine, etc. 
Hydrogenated palm oil, Vax, 
Lecithin (soy), etc. 
Aquatics 
Carrageenans, 
Alginate, 
Agarose. 
  
Animals or 
microbes 
Xanthan, 
Dextrose, 
Chitosan, 
Gellan. 
Gelatin, Collagen, 
Caseins, Albumins Lecithin (egg) 
Genetics  Recombination proteins  
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between the monomers and their sequential composition is the factor that determines the 
physical properties of the gel such as strength and the porosity of the gel33. To prepare calcium-
alginate microcapsules, a solution of alginate is poured in the form of tiny droplets into a bath 
of calcium chloride. When each droplet arrives into the calcium chloride bath the gelation 
process happens and the droplet will be solidified while maintaining its spherical shape and thus 
becomes a microcapsule34.  
 
2+ 
Figure 2. Different sequences (blocks) found in a linear chain of Alginic Acid. M = β-D-
mannuronic acid. G = α-L-guluronic acid. 
Figure 3. "Egg box” model of gel formation resulting from the crosslinking of alginate chains 
using calcium ion (adapted from references 31 and 32 ). 
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The encapsulation method using calcium alginate gels was chosen in our research because 
of its mild encapsulation conditions for biomolecules, non-toxicity, low cost and its ease of use. 
The characteristics of microcapsules such as permeability and wall thickness can also be easily 
controlled by changing the encapsulation parameters. Some of the drawbacks associated with 
this method are low stability in the presence of citrate, lactate and phosphate (most likely 
because of their affinity for calcium ion) and also high porosity of the membrane which may 
result in leakage of the immobilized biomolecule35. The porosity of such microcapsules allows 
low molecular weight substrates such as glucose and oxygen molecule (in this study) to pass 
through the microcapsule’s wall; therefore, they can diffuse in and out of the microcapsule.  
Chitosan is a linear polysaccharide composed of β-(1-4)-linked D-glucosamine (de-
acetylated unit) and N-acetyl-D-glucosamine (acetylated unit). Chitosan is derived from its 
natural source, chitin, which is a long-chain polymer of a N-acetylglucosamine abundantly 
found in exoskeletons of crabs, lobsters, shrimps and insects36. The structure of these two 
biopolymers are shown in Figure 4. 
There are several methods to prepare alginate-chitosan microcapsules. Basically chitosan 
has an ionotropic affinity for alginate (Figure 5). A one-stage preparation process involves 
droplet addition of alginate solution into an aqueous solution of chitosan which results in 
microcapsule formation comprising an alginate core and a chitosan layer. The opposite process 
is also possible to prepare chitosan core microcapsules with an alginate layer by pouring 
chitosan solution in the form of small droplets into an alginate bath33. In a two-stage procedure, 
Figure 4. Chitosan formation from the deacetylation of its natural source, chitin. 
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calcium-alginate microcapsules are prepared (Section 2.1) followed by incubation in a solution 
of chitosan to cover them with an extra chitosan layer for which the procedure will be discussed 
in Section 2.2. 
1.4.2. Encapsulation methods 
In general microencapsulation procedures are performed in three steps37. The first step is 
the addition of the biomolecule, or the species which is to be encapsulated, to the encapsulation 
matrix. This step normally involves the dissolution of the species to be encapsulated into the 
matrix. The second step includes liquid/liquid or liquid/air mechanical dispersion of 
encapsulation matrix and the third step is to stabilize microcapsules either by chemical methods 
such as polymerization or by physical methods such as evaporation, solidification, coalescence 
or by physicochemical methods such as gelification or coacervation.  
 Dispersion methods 
The common event in all dispersion methods is that the encapsulation matrix containing 
the target species (which are meant to be encapsulated) must be dispersed in the form of droplets 
in the stabilizing media to form microcapsules. Prilling, nebulization, emulsification and micro-
dispersion are different methods of dispersion, which are explained briefly in the following 
sections. 
Figure 5. Ionotropic affinity between alginate and chitosan. 
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 Prilling methods  
Basically, in prilling methods, a laminar flow of the encapsulating matrix and the 
biomolecule target is created by passing it through a narrow nozzle and this flow is broken up 
in to small droplets having a relatively small dispersion in size (i.e. with a maximum standard 
deviation of 10 % of the average particle size). The breaking up of such laminar flow is done by 
applying an electrostatic potential that reduces the surface tension of the flow (having flow rates 
of a few milliliters per hour) resulting in formation of small droplets. A schematic operating 
view of such nozzle is shown in Figure 6a38. It can also be performed using a vibrating nozzle 
which works well with low viscosity solutions and higher flow rates (a few liters per hour). 
Other prilling methods involve cutting off the laminar jet using a rapidly rotating disk (Figure 
6b38) or grid, which are effective for higher viscosities (more than 200 mPa·s). 
In our study we used the vibrating nozzle prilling method because it gives narrow size 
dispersion of the beads and also because of its compatibility to operate with the viscosity of 
sodium alginate solutions.  
Figure 6. a) Schematic operation view of a laminar flow breaking up using an electrostatic 
potential. b) Laminar flow breaking up using a rotating disk. (reproduced from reference 38) 
a)                                                                 b) 
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 Nebulization 
Nebulization or spray-drying, is a technique in which a flow of the encapsulation matrix 
is passed through a liquid/air nozzle or sometimes it is jetted to the surface of a spinning disk at 
high speed. The droplets formed using this method normally have a relatively wide dispersion, 
i.e. standard deviation of 30 – 50 % of the average particle size. The source of such a wide 
dispersion is the use of turbulent flow instead of a laminar flow in comparison with prilling 
methods. The advantage of this method is the availability of its commercialized equipment in 
industry for large scale productions. 
 Emulsification 
In this method the encapsulation matrix containing the target species is dispersed in 
another immiscible liquid and the small droplets are formed with the help of violent agitation 
using a turbine or stirrer. The droplets may have a wide particle size dispersion (standard 
deviation of 30-50 %) with the high level of agitation there is a possibility of denaturing the 
target species; for instance, in case of living cells, they may get disrupted under strong agitation.  
For industrial large scale productions (tons per hour), a system of continuous flow has been 
designed using static mixers. 
 Microdispersion 
The principle of microdispersion is the same as emulsification, which is described in 
Section 1.4.2.1.3, but the dispersion of two immiscible liquids is done with the help of a 
surfactant. The average droplet size is relatively small (less that one micrometer) and 
thermodynamically speaking, such micro-emulsions are generally more stable than normal 
emulsions.  
 Stabilization methods 
After creating small droplets of the encapsulation matrix in the previous dispersion step, 
a stabilization method is required so that they are solidified to form microcapsules while 
trapping the target species inside them. The solidification of hot matrices (previously melted) 
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can easily be achieved by cooling them to the temperature where they become solid once more. 
Sometimes it is possible to evaporate the solvent of the encapsulation matrix using dry hot air 
and the technique is therefore called evaporation. Many of the polymers used as the matrix of 
encapsulation can be jellified in a jellification process either by using low temperature or certain 
chelating ions. For instance, agarose can be jellified by lowering the temperature and alginate 
can be crosslinked using calcium ions. In the polymerization method, a polymeric network is 
formed by the polymerization of the monomeric units in the presence of the agent to be 
encapsulated. For instance, in an emulsion we may incorporate two different monomers, one in 
each phase. These two monomers can react with each other to create a polymer at the interface 
of the two phases i.e. around each droplet. In the coacervation method, the precipitation of a 
polymer is induced by changing the physico-chemical parameters of the media such as acidity, 
ionic strength, etc.  
In our study we used the jellification process of alginate using calcium ions because of the 
mild conditions for stabilization of microcapsules in the presence of biomolecule targets (GOx 
in this case) without adding a reactive agent or altering the temperature, which could be 
devastating to the biomolecule and its functionality. 
1.5. Enzymatic activity 
Enzymes are catalysts in biochemical reactions essential to the functionality of living 
systems. Each enzyme has an active site that interacts with a substrate to catalyze the latter’s 
transformation to the products. Despite the similarity of the catalysis principles between the 
enzymes and non-protein based catalysts, enzymes have unique properties in their performance. 
An enzymatically catalyzed reaction rate is usually enhanced to the order of 106 to 1012 times39. 
The condition for optimal activity of most of enzymes is quite moderate, i.e. operating 
temperature of below 100˚C, atmospheric pressure and a pH value almost neutral. The substrates 
and the reactants of each enzyme are specific to a great extent. The activity of an enzyme is 
tunable by adjusting the regulatory parameters such as allosteric control (modification of an 
enzyme to induce a change in the shape of the enzyme to change the interaction of the active 
site with the substrate)39 and covalent modification of the enzyme, for instance covalent 
bioconjugation of the enzyme and silver NPs40. The choice of GOx in this study was based on 
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the fact that this enzyme is well known and characterized to a high extent and also it catalyzes 
a reaction whose product (hydrogen peroxide) has antibacterial properties. 
1.5.1. Glucose oxidase overview 
GOx (β-D-glucose: oxygen 1-oxireductase) is a flavoprotein that catalyzes the oxidation 
reaction of β-D-glucose. This enzyme can be produced and purified from different fungi among 
which Aspergillus niger (Figure 7a41) and Penicillium species (Figure 7b42) are the most 
common sources of this enzyme. Perhaps Aspergillus niger is the most conventional source of 
GOx meanwhile the enzyme produced from Penicillium species has a more efficient enzymatic 
activity. Different types of GOx from different sources have different detailed compositions but 
all of them have in common a co-factor, flavine adenine dinucleotide (FAD), which is tightly 
entangled in the polypeptide chain but not covalently attached to the protein. This unit plays an 
important role in the activity of GOx43.  
As mentioned before, GOx catalyzes the oxidation reaction of β-D-glucose to D-glucono-
δ-lactone using molecular oxygen as an electron acceptor (Equation 1). As shown in Figure 844, 
the FAD co-factor plays an important role in the catalytic activity of the enzyme by participating 
in the oxidation-reduction reaction. In the reductive half-reaction, glucose is oxidized to 
glucono-lactone (which is subsequently hydrolyzed to gluconic acid) while FAD is reduced to 
a) b) 
Figure 7. a) GOx from Aspergillus niger (adapted from reference 41) and b) GOx from 
Penicillium amagasakiense (adapted from reference 42). 
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FADH2. In the oxidative half-reaction, FADH2 transforms back to FAD while giving an electron 
to molecular oxygen and reducing it to hydrogen peroxide. 
Equation 1 ߚ െ ܦ െ ݈݃ݑܿ݋ݏ݁ ൅ ܱଶ ீை௫ሱۛሮ ܦ െ ݈݃ݑܿ݋݊݁ߜ݈ܽܿݐ݋݊݁ ൅	ܪଶܱଶ 
1.5.2. Glucose oxidase applications 
GOx has been widely used in biotechnology and the pharmaceutical, food and beverage, 
electronics and textile industries43. In pharmaceutical and clinical chemistry, GOx is the enzyme 
used in nearly all types of glucose biosensors. The glucose biosensor for diabetes monitoring is 
an important field of application for this enzyme and it is even in some cases lifesaving. These 
biosensors are extensively used to monitor and detect the blood sugar fluctuations for patients 
having diabetes who are prone to hyperglycemia (high blood glucose content) or to 
hypoglycemia (low blood glucose content). This enzyme also can be used to prepare oral care 
products thanks to bacteriocide properties of H2O2 which is produced during the oxidation 
reaction.43  
Also the presence of glucose in some food may boost the growth of harmful 
microorganisms which reduces the food’s shelf time and produces unwanted bad taste and 
Figure 8. Details of the oxidation reaction of glucose (adapted from reference 44). 
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inconvenient color. Therefore, in food and beverage industry GOx is successfully used to 
remove the residual glucose content from food or beverages to increase their durability and shelf 
time. To remove the H2O2 produced in food products, the use of catalase is favorable to 
transform H2O2 to water and oxygen. For instance, during the production of egg powder, using 
the combination of the two enzymes, GOx and catalase, during the drying process prevents the 
appearance of the brown color. Also it is used to remove the oxygen from the top of the bottled 
beverages and food packing. Moreover, the gluconic acid (produced form hydrolysis of D-
glucono-δ-lactone) can act as a food additive for acidity regulation purposes.43 
In the electronics industry, bio-electronic devices need biofuel cells as a power supply. 
GOx is one of the biocatalysts that is used in biofuel cells to convert biochemical energy to 
electrical energy. In one of the approaches, enzymatically catalyzed oxidation reaction of 
glucose can be used in anode, coupled with the enzymatically catalyzed reduction of dioxygen 
in cathode using dioxygen-reducing enzyme such as laccase. All material used in such biofuel 
cells are biocompatible and biodegradable.43 
In textile industry, the produced H2O2 can be used as the bleaching agent for scoured 
woven cotton fabric also the gluronic acid can act as the stabilizer in the process so there is no 
need to use a stabilizing agent. Also the combination GOx/ hydrogen peroxidase (HRP) can be 
used to oxidize the colored components since H2O2 is produced and then it is rapidly consumed 
to oxidize and subsequently bleaches the natural fibers.43  
In this project, the production of H2O2 from the reaction of glucose with oxygen will be 
used to deactivate pathogens.  
1.5.3. Enzyme kinetics 
As mentioned before, enzymes are biological catalysts but their function is much more 
complicated than normal catalysts. Some enzymes conduct a reaction on a single substrate while 
others may act on two or more substrates39. In the simplest case where the enzyme deals with 
one single substrate, it has been found that in low concentrations of the substrate, the rate of the 
reaction varies linearly with the initial concentration of the substrate which means the reaction 
is following first-order kinetics while at high concentrations of the substrate, the reaction rate 
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becomes independent of the initial substrate concentration which means the kinetics of the 
reaction has a zero-order pattern. The change in the concentrations of the different species 
involved in a single substrate enzymatic reaction is demonstrated in Figure 945. 
The behavior of the enzymes was first studied and defined in 1913 by Leonor Michaelis 
(1875-1949) and Maud L. Menten (1879-1960) as Equation 246: 
Equation 2   ܧ ൅ ܵ ⇄ ܧܵ → ܧ ൅ ܲ 
where E, S and P are the enzyme, substrate and the product, respectively and ES is the enzyme-
substrate complex, k values are rate constants for each reaction. In Equation 2, when the 
concentration of the substrate is much bigger than the concentration of the enzyme, it can be 
assumed that all the enzyme is transformed to the enzyme-substrate complex so the second step 
of the reaction is the rate-determining step (RDS) so the rate of the reaction (υ) can be expressed 
as: 
Equation 3   ߭ ൌ ௗሾ௉ሿௗ௧ ൌ െ
ௗሾௌሿ
ௗ௧ ൌ ݇ଶሾܧܵሿ 
Figure 9. Concentration change of the species in a single substrate enzymatic reaction. S: 
substrate, E: enzyme, P: product, ES: enzyme-substrate complex (reproduced from 
reference 45). 
k1                     k2 
k-1 
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The steady state assumption which allows us to assume that the change in the concentration of 
ES in time equals zero, provides an estimation for the concentration of the enzyme-substrate 
complex: 
 Equation 4   ሾܧܵሿ ൌ ௞భሾாሿబሾௌሿ௞షభା௞మା௞భሾௌሿ 
Where [E]0 is the initial concentration of the enzyme and at any time point and it equals the 
concentration of free enzyme plus the concentration of the enzyme in the form of the complex 
with substrate ([E]0 = [E] + [ES]). By substitution of Equation 4 in Equation 3 and also 
considering the fact that the maximum rate of the reaction occurs when the substrate exists at 
high concentrations which converts all of the enzyme to ES (i.e. Vmax=k2[E]0), further 
rearrangement of the Equation 3 results in: 
 Equation 5   ߭ ൌ ௏೘ೌೣ	ሾௌሿሾሺ௞షభା௞మሻ ௞భൗ ሿାሾௌሿ
 
By defining ܭ௠ ൌ	 ௞షభା௞మ௞భ 		as Michealis-Menten constant, Equation 5 can be written as: 
Equation 6   ߭ ൌ ௏೘ೌೣ	ሾௌሿ௄೘ାሾௌሿ  
Two boundaries of substrate concentration can be imagined, one where [S] is much bigger than 
Km, as can be seen in Figure 1045, the rate of the reaction reaches its maximum value and 
independent of [S] which means it is zero-order. The other extreme is met when [S] is much 
lower than Km, so the rate of the reaction becomes first-order (Equation 7) and it is preferably 
said that no rate determining step exists in the kinetics of the reaction46. 
 Equation 7   υ ൌ ௞మ	௄೘ 	ሾܧሿ଴ሾܵሿ 
It can be easily perceived from Equation 6, when the rate of reaction is at one-half of Vmax, the 
value of [S] equals the value of Km. Smaller values of Km indicates that the saturation of the 
enzyme (total conversion of the enzyme to enzyme-substrate complex) occurs at lower substrate 
concentrations and thus, the affinity of the enzyme for its substrate is relatively high. Greater 
values of Km, similarly means that the affinity of the enzyme for the substrate in relatively low 
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so higher concentrations of the substrate are needed to saturate the enzyme. In our study, we 
will make sure to operate at Vmax to be able to measure the enzymatic activity of GOx. 
1.6. Escherichia coli (E. coli) 
In our study, E. coli was selected as a representative model of pathogens.  E. coli is an 
abbreviation for Escherichia coli (Figure 11)47 that is attributed to a group of bacteria that reside 
in the intestines of humans and animals. They are mostly found in contaminated food or water 
so disinfecting processes on food and water such as proper cooking of meat and raw vegetables, 
water treatments, pasteurization of dairy products and juices as well as controlled contact with 
animals in petting zoos and farms can highly reduce the risk of spreading such bacteria. 
Infections of E. coli are both gastrointestinal and extraintestinal. Severe stomach cramps, 
diarrhea, vomiting, a mild fever for certain strand of bacteria kidney failure are the symptoms 
and adverse effects of E. coli on human body48. Since the term biotechnology first emerged 
during a meeting at a Hawaiian delicatessen in 1972, E. coli has been extensively used for 
research purposes in microbiology and biological engineering research specially as a host for 
propagating and cloning engineered plasmids49. In our study, E. coli K-12 was used as a 
Figure 10. The plot of the initial rate of the reaction versus the concentration of substrate 
(reproduced from reference 45). 
22 
 
representative pathogen because there are non-pathogenic strains of this bacteria which can be 
safely manipulated in laboratories for research purposes. 
1.6.1. Bacterial growth 
Growth is a characteristic of all living organisms and is a general definition used when a 
living organism increases its cellular mass or the number of cells. About half a century ago (or 
even earlier), researchers were able to understand the general laws of bacterial growth50. This 
growth is greatly affected by environmental factors such as pH, temperature, osmotic pressure, 
the content of nutrients, etc. Bacteria are unicellular microorganisms and in favorable conditions 
for their growth, they start consuming the nutrients in the media and attain certain size and 
consequently, they divide into two cells through a binary fission process. In this process a parent 
bacteria cell is divided into two new daughter cells while its genetic material (DNA) duplicates 
and each daughter cell receives one copy of DNA51. Different steps of such reproduction process 
for an E. coli bacteria cell is schematically illustrated in Figure 1252. Generally, prokaryotic 
organisms have chosen binary fission as their primary method of reproduction. 
Figure 11. Scanning electron micrograph of Escherichia coli, grown in culture and adhered 
to a cover slip (reproduced from reference 47). 
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The growth pattern for each bacteria is varied in different ecological conditions. The 
number of cells (Nt) after a certain time (t) can be predicted from Equation 8 where N0 is the 
initial number of bacteria cells and τ is the time required for a single cell to grow and duplicate53. 
Equation 8   ௧ܰ ൌ ଴ܰ2௧ ఛൗ  
The bacterial growth curve is an indication of a bacteria’s population by plotting the binary 
logarithmic scale of the number of cells at each time point versus time. The resulting graph is 
illustrated in Figure 1352. This graph exhibits four distinctive stages of the bacterial life cycle 
provided that bacteria are cultured in an isolated culture media where no additional nutrients or 
space are added and also no waste or dead cells are removed from the culture media. The first 
stage is the lag phase which occurs after the bacteria are added to the culture medium. In fact, 
this time elapse before the growth phase (second stage) is the period of time required for the 
organisms to adapt themselves to the new environment so the population growth at this period 
close to 0. The second stage is the growth phase and the binary logarithm of the number of cells 
grows linearly with time according to Equation 9 obtained by rearranging Equation 8. 
Equation 9   ݈݋݃ଶ ቀ ௧ܰ ଴ܰൗ ቁ ൌ ݐ ߬ൗ  
Figure 12. Different steps of a binary fission process in E. coli cell (reproduced from 
reference 52). 
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This growth phase which also called log phase is the period of optimal population growth 
depending of the growth conditions. Eventually, however, when the growing population 
approaches the upper limit, the media runs out of nutrients and space. At this point, the bacterial 
population levels off and population growth becomes nearly 0 again. This stage, called the 
stationary phase and may last for a long period of time. The last stage of this life cycle is called 
the death phase. The waste and dead cells begin to accumulate and the population declines 
because of the lack of nutrients. Some species that are able to form spores can persist beyond 
this stage and can regenerate a population if conditions once again become favorable. In this 
study, the effect of H2O2 generated by the enzymatically catalyzed reaction of glucose on the 
lag phase of the bacterial growth were studied.  
Figure 13. Life cycle of a bacterial growth (reproduced from reference 52) . 
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1.7. Structure of the thesis 
As mentioned in Section 1.1, the goal of this research is to develop a generic antibacterial 
platform that relies on the use of immobilized enzymes and can be applied to current paper 
production processes. The design, preparation and characterization of such a platform and its 
impact on the enzymatic activity is presented in the current study. This antibacterial platform 
was designed to trap GOx in microcapsules consisting of an alginate-calcium matrix. The 
enzymatic activity of GOx in the presence of its substrates (glucose and O2) produces an 
antibacterial agent, H2O2, which leaches out of the microcapsules and decomposes pathogens in 
the media. In this regard, non-pathogenic bacteria, E. coli K-12, was proposed as a model. Since 
this platform is destined to be used in a laboratorial papermaking process (in future research) 
and it will be incorporated onto paper, it has to be structurally robust against mechanical stress. 
Therefore, a layer of chitosan was used to cover the surface of alginate microcapsules. Also, to 
be able to capture low amounts of pathogens on the surface of microcapsules and to increase the 
efficiency of the system, the immobilization of a given antibody (selective to a certain pathogen) 
was considered. Since antibodies against E. coli are expensive and available only in small 
amounts, human Immunoglobulin G (human IgG) was selected as a model antibody. It was 
assumed that developing a successful immobilization method for this model antibody, while 
maintaining the enzymatic activity of encapsulated GOx, could be applied to other antibodies 
with similar structure. After the preparation of this platform, its antibacterial properties against 
our model pathogen were investigated. It is important to note that the application of this 
antibacterial platform onto paper was not pursued in this research and will be the subject of the 
future studies. 
As will be presented in following sections of this research, the encapsulation of GOx 
resulted in a reduction in its enzymatic activity. Therefore, we came up with the idea that 
immobilization of GOx on gold nanoparticles (NPs), before encapsulation, could possibly 
increase its enzymatic activity. The goal of this sub-project (Chapter 5) was to compensate the 
enzymatic activity loss during the encapsulation process and also to increase the encapsulation 
efficiency. 
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This thesis is composed of seven chapters. The current chapter includes an introduction to 
the scientific notions of this research and provides background knowledge for readers to be able 
to understand this project. The second chapter presents the detailed description of all materials, 
protocols, methods and the instruments with which the research was carried out. All the 
observations, measurements and data regarding the preparation of encapsulated GOx are 
brought to the reader in chapter three. The results and discussion regarding the study on 
antibacterial properties of our microcapsules are presented in chapter four along with the 
interpretations and discussions to justify those obtained results. Chapter five contains the data 
regarding the immobilization of GOx on gold NPs and the effect of this immobilization on the 
enzymatic activity. Since this part of the project is considered as a sub-project (additional to the 
main stream of the project), the introduction and experimental procedures for this part of the 
study are presented in the same chapter as the corresponding results and discussion. The sixth 
chapter presents the conclusion of this project and opens a window to the future possible works 
which lie ahead. Finally, the seventh chapter of this thesis provides all the implemented 
bibliographic references to support the ideas discussed in the thesis.  
 
 
 
Chapter 2. Instruments and experimental methods
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2.1. Enzyme encapsulation 
The encapsulation of enzyme is achieved by ionotropic jellification of small droplets of 
alginate solution, which contain GOx. This process also involves laminar jet break-up of the 
solution. The encapsulation efficiency is then determined to evaluate the amount of encapsulated 
enzyme.  
2.1.1. Laminar jet break-up encapsulation 
 Method 
For the preparation of encapsulated enzyme, a laminar jet break-up54 with a vibrational 
nozzle method of dispersion was used in combination with a further gelification of the 
encapsulation matrix as a stabilization method using the Inotech Encapsulator® IE-50 R (Figure 
14) which is a semi-automated instrument for encapsulation of biomolecules and pharmaceutics. 
Setting different instrumental parameters helps us to control and determine the size of 
microcapsules (beads). The bead size varies from 100 µm to > 1000 µm in diameter according 
to the encapsulation parameters and the size of the nozzle with size dispersion of about 5 % in 
Figure 14. Inotech Encapsulator® IE-50 R. 
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terms of relative standard deviation. Bead production rate is rather high i.e. 50-3000 beads per 
second depending on the bead size and viscosity of the encapsulation-product mixture. This 
technique possesses low sheer stress which results in high cell viability when microorganisms 
undergo encapsulation. The schematic view of the Inotech Encapsulator® IE-50 R54 is shown in 
Figure 1554 along with presentation of different parts of the instrument. The encapsulation 
Figure 15. Schematic representation of Inotech Encapsulator® IE-50 R (reproduced from 
reference 54). 
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solution is introduced into the system via a syringe pump with laminar flow before it reaches 
the vibrating nozzle the laminar flow is created. Thus, the flow is broken up resulting in the 
formation of microscopic droplets. Then these micro droplets are dispersed using an electrostatic 
field and incubated in the gelification bath (containing Ca2+ ions).  
 Materials 
Alginic acid sodium salt from brown algae (low viscosity) and GOx from Aspergillus 
niger were purchased from Sigma-Aldrich and were used to prepare encapsulation matrix-
enzyme mixture. Calcium chloride dihydrate (CaCl2.2H2O) from Sigma-Aldrich was used to 
prepare the jellification solution (bath). The water used in all procedures was purified by a 
MilliQ system to a resistivity of 18 MΩ.cm.  
 Protocol 
A solution of alginate (0.7 m/v %) was prepared by dissolving sodium alginate in water 
along with stirring and heating under the boiling point to minimize evaporative losses. The 
encapsulation matrix-enzyme mixture was prepared by adding a weighed amount of GOx 
powder to alginate solution and then completing the solution to volume with water. The final 
concentration of enzyme in the mixture was set to be approximately 0.5 mg/ml (the exact 
concentration of the enzyme was measured in the encapsulation efficiency evaluation step). This 
mixture was then filtered using a Whatman nylon 5 µm filter before introduction to the 
Encapsulator instrument. The encapsulation parameters, which were optimized for the quality 
of beads and their dispersion, are given in Table 2. After the formation of microcapsule in 
calcium chloride bath, they were incubated for 30 minutes then they were simply filtered out 
using a vacuum Buchner funnel and filter paper followed by several rinsing steps using the 
calcium chloride solution (0.1 M). 
Table 2. Glucose oxidase encapsulation parameters. 
Encapsulation Parameter Value Encapsulation Parameter Value 
Syringe pump flow rate 2.6 ml/min Electrostatic charge voltage 1.41 kV 
Frequency 1376 Hz Calcium chloride bath concentration 0.1 M 
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2.1.2. Encapsulation Efficiency 
To evaluate the encapsulation efficiency, we needed to measure how much enzyme is 
encapsulated. Therefore, the Bio-Rad protein assay was used to analyze the protein content of 
the calcium chloride bath which is an indicator of the amount of GOx lost during the 
encapsulation process. Knowing the total amount of the enzyme introduced to Inotech 
Encapsulator®, we were able to calculate indirectly the encapsulation efficiency. 
 Method for protein assay 
The Bio-Rad protein assay is a method for the determination of solubilized protein based 
on the method of Bradford55 that involves the addition of an acidic dye to the protein solution 
and the formation of protein-dye complex that absorbs light maximally at a different wavelength 
than its unbound form. The absorbance of light is linearly proportional to the concentration of 
the complex, which correlates to the concentration of protein in a given solution. In this case, 
the complex forming dye is Coomassie® Brilliant Blue G-250 (Figure 16) and its maximum 
absorbance wavelength shifts from 465nm to 595 nm once it is bound to proteins. The unbound 
form of the dye has three charge states: cationic form (red), neutral form (green) and anionic 
form (blue). However, when it binds to protein, it is converted to a stable un-protonated anionic 
blue form (λmax=595 nm). It has been found that Coomassie blue primarily binds to aromatic 
and basic amino acid residues especially arginine56. In this method the calibration curve can be 
obtained using Bovine Serum Albumin (BSA) and provides us with a linear range of 0.04 to 0.2 
Figure 16. Coomassie® Brilliant Blue G-250. The protein complexation dye in Bradford 
protein assay. 
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mg/ml or using Bovine Gamma Globulin with a linearity ranging from 0.04 to 0.3 mg/ml57. 
These concentrations refer to the final concentration of the protein in the spectrophotometric 
cell. In our study since no standard solution is commercially available for GOx, we chose BSA 
as the protein standard for the calibration curve. 
 Materials  
Protein assay dye reagent concentrate was purchased from Bio-Rad Laboratories, Inc. and 
BSA protein micro standards (1 mg/ml) from Sigma-Aldrich. 
 Protocol 
Dye reagent was prepared by diluting 1part dye reagent concentrate with 4 parts MilliQ 
water. Three to five diluted stock solutions of BSA standard were prepared ranging from 0.2 to 
0.9 mg/ml and 100 µl of each standard solution is added to 5.0 ml of the dye reagent and then 
vortexed for a few seconds. These solutions were incubated at room temperature for at least 5 
minutes (but not for more than one hour) and their absorbance was measured using a Varian 
Cary 100 Bio UV-Vis Spectrophotometer at λ=595 nm. Sample preparation was carried out 
similarly and to prepare the blank sample 100 µl of calcium chloride (0.1 M) was added to dye 
reagent to represent the matrix of calcium bath. 
2.2. Modification of alginate microcapsules with chitosan 
 Method 
Taking the affinity of chitosan for alginate to our advantage, we were able to cover 
microcapsules with an extra layer of chitosan. Different methods are available for such 
modification. One of these methods is simple incubation of microcapsules in a solution of 
chitosan (0.15 % w/v) in acetate buffer (50 mM)  pH 5.0 containing calcium chloride (0.1 M)33. 
The high concentration of calcium cations in the incubation solution stabilizes microcapsules 
and prevents their rupture resulting from diffusion of calcium from microcapsules out to the 
solution. 
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 Materials 
Acetate buffer was prepared using sodium acetate trihydrate (CH3COONa.3H2O) that was 
purchased from American Chemicals Ltd. and glacial acetic acid A.C.S. reagent from J.T.Baker. 
Chitosan, medium molecular weight (deacetylation degree of 75-85 %) was purchased from 
Sigma-Aldrich. 
 Protocol 
A solution of chitosan (0.15 % w/v) in acetate buffer (50 mM) pH 5.0 containing calcium 
chloride (0.1 M) was prepared by dissolving chitosan and calcium chloride in acetate buffer with 
vigorous shaking for at least 45 minutes. Then approximately 6.0 g of microcapsules were added 
to 200 ml chitosan solution and allowed to incubate overnight. Microcapsules were then 
recovered on filter paper using a vacuum Buchner funnel and washed with calcium chloride 
solution (0.1 M) and stored at 4˚C for further analysis. 
2.3. Microcapsule characterization 
Confocal laser scanning microscopy (CLSM) was used to take fluorescent images of the 
microcapsules. To do so, chitosan must be labeled with fluorescein isothiocyanate (FITC), a 
very common fluorophore that can easily react with amino groups on chitosan structure (Figure 
17). Also to determine the presence of nitrogen that originates from chitosan in the composition 
of alginate-chitosan microcapsules (without encapsulated GOx), Elemental Analysis technique 
was used.  
Figure 17. Fluorescein isothiocyanate (FITC) reaction with amino groups. 
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2.3.1. Imaging methods 
 Optical imaging 
Traditional optical transmission images were taken using a MOTIC BA310 optical 
microscope. 
 Confocal laser scanning microscopy imaging 
Confocal laser scanning microscopy (CLSM) is a useful imaging technique that has the 
ability to produce images from different depths of a thick sample. The images are taken point 
by point and out-of-focus information is eliminated resulting in high resolution 3D images. The 
CLSM technique was developed by Marvin Minsky in 195758 and grew in popularity over the 
proceeding decades thanks to advances in laser technology and computer science. The 
fluorescence signal is greatly improved since an intense laser or arc-discharge source is usually 
used for excitation which improves fluorescence emission intensity. The detector for such 
devices is usually a photomultiplier tube (PMT) which has high quantum efficiency in the near-
UV, visible and near IR.  
 Materials 
Fluorescein isothiocyanate (FITC) Isomer I was purchased from EMD Chemicals. 
 Method 
In our research, a Leica TCS SP5 II CLSM58 equipped with three point laser sources 
controlled by high speed acousto-optic tunable filters was used which is schematically shown 
in Figure 1858 . The excitation laser sources for this device include helium neon (λ=633 nm), 
diode-pumped solid state (DPSS: λ=561 nm), and argon ion (λ=458/488/514 nm). The source 
that we used for our study was the 488 nm argon ion line and the emission signal was captured 
at 500 nm. These excitation and emission wavelengths are standard for fluorescein 
isothiocyanate (FITC), which was our fluorophore label.  
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In order to label chitosan with fluorescein isothiocyanate (FITC), a certain amount of 
chitosan was dissolved in acetic acid 0.1 M to reach the final chitosan concentration of 1 % m/v. 
The use of acetic acid allowed us to dissolve chitosan in an aqueous solution.  FITC was 
dissolved in anhydrous methanol (2 mg/ml) and in order to react FITC with chitosan, 50 ml of 
FITC in methanol solution was added to 100 ml of the aforementioned chitosan solution along 
with addition of an extra 100 ml of anhydrous methanol. This mixture was agitated in the dark 
for three hours. Precipitation of FITC- tagged chitosan was done using a 1 L of NaOH solution 
(0.1 M) then dissolved in acetate buffer (5mM at pH 5.0) followed by a dialysis process in the 
same buffer during three days at 4˚C and by changing the dialysis solution twice per day to 
remove the excess amount of FITC .The recovered FITC-labeled chitosan solution was used to 
cover our microcapsules through procedure described in Section 2.2.1.1. 
Figure 18. Confocal laser scanning microscope Leica TCS SP5(reproduced from 
reference 58). 
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2.3.2. Elemental analysis 
Elemental analysis was used to determine the elemental composition of a substance which 
can provide us the percentage of the elements, C/H/N/S, with a good precision. The analysis 
was performed at Laboratory of elemental analysis, Département de chimie, Université de 
Montréal using EAS1180, Fisons instruments S.p.A.59 
2.4. Antibody Immobilization 
In this study, human immunoglobulin G (IgG) was used as a model antibody to verify the 
possibility of antibody immobilization onto the external surface of the designed microcapsule-
based platform. The choice of this model antibody was made according to its availability and 
cost since an IgG specific for our model pathogen, E. coli, was not available in large quantities 
with a reasonable cost. The chosen immobilization method is a covalent coupling reaction using 
glutaraldehyde. 
2.4.1. Method 
Glutaraldehyde covalent coupling method could be used to immobilize antibodies on 
alginate-chitosan microcapsules. Glutaraldehyde (Pentane-1, 5-dial) is one of the most well-
known and easy to handle agents for protein cross linking that has been used in many fields of 
research and science. The reactivity of glutaraldehyde toward protein originates from the 
reaction between glutaraldehyde’s single linear molecular form (because in an aqueous solution, 
glutaraldehyde can form a cyclic hemiacetal as well as dimers, trimers, etc.) and several reactive 
functional groups residues on the body of protein. In fact, glutaraldehyde can react with amine, 
thiol, phenol and imidazole groups on amino acid side-chains60. It is also a simple and mild 
coupling agent to immobilize biomolecules (enzymes and antibodies) on water insoluble carriers 
because the reaction happens in aqueous buffer solution under conditions close to physiological 
pH. Different possible reactions between proteins and glutaraldehyde are summarized in Figure 
1960.  
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The glutaraldehyde coupling reaction has three different main steps61. In the first step our 
alginate-chitosan microcapsules are incubated with glutaraldehyde to activate the amino groups 
of chitosan. Ideally glutaraldehyde molecules are attached to the surface of microcapsules via 
one of its formyl group (formation of imine bond) while the other end is free for the next step 
of immobilization process. The second step includes the incubation of glutaraldehyde-activated 
microcapsules with human IgG as a model antibody. In this step the incubation solution must 
contain calcium ions to prevent the swelling of microcapsules as a result of calcium ions removal 
from microcapsules by the antibody because calcium ion tends to bind to the antibody while 
reducing its immunoaffinity. Adding 5 mM as the maximum concentration of calcium ion in the 
reaction buffer prevents stability loss of microcapsules but maintains the affinity of the 
antibody61. In the final step, unreacted free ends of glutaraldehyde are end-capped with glycine 
to reduce the risk of unwanted crosslinking reactions. A schematic presentation of these steps 
are shown in Figure 20.  
Figure 19. Reactions of glutaraldehyde with proteins under acidic or neutral conditions. The 
labels I, IV and V refer to different forms of glutaraldehyde in the original document. I: 
Monomer (single molecular from). IV: Cyclic hemiacetal form. V: Polymeric species of cyclic 
hemiacetal form (reproduced from reference 60) . 
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2.4.2. Materials 
Anhydrous sodium tetraborate (Na2B4O7), sodium chloride, glycine (C2H5NO2), 
glutaraldehyde solution grade I, 50 % (C5H8O2) were all supplied by Sigma-Aldrich. IgG from 
human plasma (MW=150 kDa) was purchased from Athens Research & Technology, Inc. 
2.4.3. Protocol 
A mass of 0.50 g of microcapsules (previously dried on filter paper) was added to 2 ml of 
borate buffer (0.1 M) pH 7.2 containing CaCl2 (5 mM) and glutaraldehyde (0.25 % w/v) and 
stirred at room temperature for 60 min. Microcapsules were then filtered out on filter paper using 
a Buchner funnel and rinsed 4 times with 3 ml of borate buffer (0.1 M) pH 7.2 containing CaCl2 
(5 mM) to remove the excess amount of glutaraldehyde completely. Glutaraldehyde-activated 
microcapsules were added to a solution of the same buffer containing CaCl2 (5 mM) and human 
IgG (0.2 mg/ml) and stirred at 4˚C. After 60 min, 0.05 ml of glycine solution (1 M) was added 
and incubated for another 60 min. Finally, microcapsules were filtered out and rinsed once with 
NaCl (0.5M) and three times with 3 ml borate buffer (0.1 M) pH 7.2. 
Figure 20. Different steps of antibody immobilization on alginate-chitosan microcapsules. 
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2.5. Antibody immobilization confirmation 
2.5.1. Method 
 To check if covalent binding of the antibody was successful, the Matrix Assisted Laser 
Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF-MS) technique was 
used. Laser desorption/ ionization (LDI) technique was invented half a century ago. It is a 
technique in which the dry sample is hit by a high intensity laser beam that results in desorption 
and ionization of the sample for further analysis by the analyzer component of the mass 
spectrometer. Its drawback in comparison with other similar desorption techniques such as field 
desorption (FD), plasma desorption (PD) and fast atom bombardment (FAB) is that its 
application is limited to low-mass organic salts and light-absorbing organic molecules and a 
tremendous effort was needed to desorb and ionize biomolecules especially when their mass 
exceeds 2000 Da. To fix this problem, large biomolecules were co-crystallized with an organic 
compound (differs for the type of biomolecule) which facilitates the desorption process and 
increases the rate of ionization. This laser desorption technique assisted by an organic matrix, 
MALDI along with a time of flight mass analyzer is capable of producing mass spectra of 
biomolecules and polymers of a few 100,000 Da.62 
2.5.2. Protocol 
A solution of sinapinic acid (20 mg/ml) in 1:1 acetonitrile: 0.2 % v/v trifluoroacetic acid 
(TFA) in water was prepared and used as the matrix material. On the MALDI plate, 
microcapsules were sandwiched between two layers of matrix since they were not soluble. First 
the surface of the allocated place on the plate was covered with the matrix (approximately a few 
microliters). After letting it dry for a couple of minutes, microcapsules were added on to the 
dried matrix. The amount of added microcapsules was not necessarily known. After drying, a 
few more small droplets of the matrix were added on top of microcapsules. The MALDI-TOF-
MS experiment was carried out using Burker’s Ultraflex TOF/TOF instrument with laser 
intensity of 70 %. Data acquisition was made in the m/z range of 20,000 to 350,000 Da, all in 
positive polarity mode with 7500-20000 laser pulses at each shot. At least 30 shots were made 
randomly on the surface of the samples, for each analysis. The samples analyzed by this 
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experiment were microcapsules with and without immobilized human IgG, all without 
encapsulated GOx.  
2.6. Activity measurements  
The enzymatic activity can be calculated by measuring the initial rate of oxidation reaction 
of glucose which is catalyzed by GOx enzyme. The oxygen content of a solution in a closed 
system decreases in the presence of GOx and its substrate, glucose. This diminution of oxygen 
content can be followed by various techniques, one of which is the oxygen electroanalytical 
technique.  
2.6.1. Method 
To measure GOx activity, the oxygen electroanalysis technique was used by plotting the 
percentage of dissolved oxygen content versus time in a closed Clark-Cell oxygen electrode 
containing glucose and encapsulated GOx. This electrochemical sensor for oxygen is based on 
the reduction of O2 on a Pt electrode and it is named after his inventor Leyland C. Clark (1959). 
To measure the partial pressure of oxygen in gas phase or in dissolved form, this electrochemical 
sensor has widely been used in environmental studies, in bacterial attack progression monitoring 
in sewage water treatments, in monitoring and controlling the O2 level in fermentation of 
alcoholic beverages as well as in medicine in monitoring of physiological analytes63. The 
detection range of dissolved O2 for this device varies from 2.84 µM (i.e. 0.01 %) to 284 µM (i.e. 
100 %) at 25˚C. The main advantage of Clark-Cell oxygen electrode for O2 detection is that its 
membrane is gas-permeable but not ion-impermeable which separates the system from the 
sensing platinum electrode (cathode). This important role of the membrane prevents electrode 
passivation and poisoning resulting from a direct contact in cases where the sensing electrode is 
placed inside the system64. 
The different parts of the Clark-Cell64 device are schematically shown in Figure 21. The 
device is comprised of two electrodes. The working electrode (cathode) is a platinum disc, 2 
mm in diameter covered with a membrane. O2 diffuses through the membrane and is reduced at 
the surface of this electrode. The counter and reference electrode is a silver ring with a surface 
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ten times larger than that of the platinum electrode and the conduction between these two 
electrodes is achieved with a solution of NaCl (3 M) which saturates a tissue paper covering the 
two electrodes. The gas-permeable membrane is made of Teflon with a thickness of 12.7 µm. 
By applying a potential to the cathode, diffused O2 is reduced (Equation 10) at the surface of 
platinum and a current flows between two electrodes which is proportional to the partial pressure 
of O2 in the system. The oxidation reaction on silver anode and the overall electrochemical 
reaction is given in Equation 11 and Equation 12, respectively. 
Equation 10   ܱଶ ൅ 2ܪଶܱ ൅ 4݁ି → 4ܱܪି 
Equation 11   ܣ݃ ൅ ܥ݈ି → ܣ݃ܥ݈ ൅ ݁ି 
Equation 12   4ܣ݃ ൅ ܱଶ ൅ 2ܪଶܱ ൅ 4ܥ݈ି → 4ܣ݃ܥ݈ ൅ 4ܱܪି 
Figure 21. Schematic view of Clark-Cell oxygen electrode (adapted from reference 64). 
Counter/Reference electrode 
with a water jacket for temperature control 
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2.6.2. Materials 
D-(+)-Glucose (C6H12O6), ACS grade reagent was purchased from Sigma-Aldrich. The 
same materials were used to prepare acetate buffer as described in Section 2.2.1.2. 
2.6.3. Protocol 
A solution of glucose (100 mg/ml), the substrate for GOx, was prepared in acetate buffer 
(50 mM) pH 5.0. For each activity measurement, either for free enzyme or encapsulated enzyme, 
2.0 ml of the glucose solution was diluted with 3.0 ml of acetate buffer in Clark-Cell oxygen 
electrode then the enzyme was also added to the solution chamber. The percentage of oxygen 
was plotted versus time and the slope of the liner region of the plot was taken in to consideration 
as the initial rate of the oxidation reaction. Throughout this thesis, the uncertainty for each 
measured data is reported as ± standard deviation (SD). 
2.7. Bacterial growth inhibition  
Preliminary studies on bacterial growth inhibition properties of the designed platform 
were carried out using E. coli K-12 as a model pathogen and cultivating them on a petri dish. 
Then the effect of enzymatic activity on the bacterial growth was studies in more detail by 
measuring the optical density of the bacteria culture media. 
2.7.1. Bacterial growth on petri dish 
 Method 
The bacteria were spread uniformly on Luria-Bertani (LB) broth culture media65 
containing agar gel in a petri dish and any antibacterial agent which is to be tested is placed on 
the central spot on a paper disc. In such a culture system, bacteria will grow on the surface of 
the gel while making the gel turbid except over the regions in which there exists some 
antibacterial effect. So anti-bacterial region stays more transparent comparing with the turbid 
surface of the agar gel.  
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 Materials 
All materials needed to prepare bacteria’s culture media were used at bacteriological grade 
and purchased from Bioshop Canada Inc.  
 Protocol 
The LB broth culture media is made by adding tryptone (10 g), yeast extract (5 g) and 
NaCl (10 g) to some MilliQ water followed by pH adjustment to 7.0 with NaOH (5 M) and 
volume adjustment to 1 L. Then the broth was autoclaved at 121 ˚C for 25 minutes. 
Sterilized warm LB broth culture media containing 2 % agar gel and 10% glucose was 
poured in a petri dish and cooled to room temperature. Then 100 µl of a saturated solution of E. 
coli K-12 (made by adding some bacteria to LB broth culture media and incubating at 37 ˚C for 
16 hours) was added on to the gel and spread uniformly to create a carpet-like layer of bacteria. 
A certain mass of microcapsules with encapsulated GOx (and microcapsules without 
encapsulated GOx for the control sample) was spread on a piece of sterilized paper disc (d=1.6 
cm). This paper was placed in the center of the petri dish and subsequently, the petri dish was 
incubated at 37 ˚C for 16 hours.  
2.7.2. Optical density measurements for bacterial growth in Luria-Bertani 
broth 
 Method 
LB broth culture media is one of the richest culture media for bacteria and provides 
essential nutrients for them to grow fast and also with a good growth yield. This culture medium 
is commonly used in steady-state bacterial growth researches and exhibits a high level of 
reproducibility. During steady-state growth studies (the middle linear section of the second stage 
of the bacteria life cycle as presented in Section 1.6.1), it is assumed that all intrinsic properties 
of the cells such as the mean volume, mass, density and the macromolecular composition of the 
cells remain constant and all extrinsic parameters such as optical density of the culture medium, 
the number of cells per milliliter, the protein content per milliliter, etc. increase doubly at the 
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same doubling time for reproduction of cells for instance, the doubling time for E. coli K-12 in 
LB broth culture media is 20 minutes. The ambient parameters such as temperature, pH and the 
composition of the medium also need to be kept constant.66 
 Materials 
All materials needed to prepare bacteria’s culture media were used at bacteriological grade 
and purchased from Bioshop Canada Inc.  
 Protocol 
Each bacteria culture was done in a sterilized 250 ml- Erlenmeyer flask by adding 95 ml 
of LB broth culture media, 5 ml of glucose (40 % w/v) in addition to the desired amount of GOx 
or microcapsules and the number of E. coli K-12 to initiate the bacterial growth. Then the 
Erlenmeyer flask was sealed and incubated at 37 ˚C under agitation. The optical density of each 
batch was measured by transferring 1 ml of the culture media in to a disposable cuvette and 
reading the absorbance (turbidity measurements) at λ=600 nm by Cary 100 Bio UV-Vis 
Spectrophotometer. All manipulations were done in the vicinity of a flame to ensure the absence 
of other bacterial contaminations.  
 
 
 
 
Chapter 3. Enzyme encapsulation 
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3.1. General objectives 
As previously mentioned in Section 1.1, the goal of the project is to develop an 
antibacterial platform that can be applied to current paper production processes, which has the 
ability to capture pathogens on its surface and to deactivate them by producing an anti-
pathogenic agent. To achieve this goal, the first phase of this research included the preparation 
of alginate microcapsules and the encapsulation of GOx at the same time. Then the surface of 
these microcapsules had to be functionalized by chitosan. Finally, the possibility of 
immobilizing human IgG (our model antibody) on the external surface of the alginate-chitosan 
microcapsules was evaluated. Control experiments were performed to confirm the successful 
modification of microcapsules after each step and the activity of GOx was also monitored after 
each modification to ensure that the enzyme is still active. So this chapter contains the result and 
discussion regarding all aforementioned steps. 
3.2. Size distribution of microcapsules 
Alginate microcapsules were transferred onto a microscope slide and were observed using 
conventional light microscopy (Figure 22). A sample of 234 microcapsules were examined 
statistically to find their size distribution. The size distribution, which was manually measured 
using the scale provided by the microscope, is presented in Figure 23 and an average diameter 
Figure 22. Optical microscopy image of alginate microcapsules. 
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of 120±20 µm was found for microcapsules prepared using the microencapsulation conditions 
described in Section 2.1.1.3. In Figure 22 microcapsules appear to be collapsed, which is due to 
the mechanical pressure of the microscope slide cover. 
3.3. Encapsulation efficiency 
The encapsulation efficiency in our study is defined as the percentage of enzyme 
encapsulated in comparison with the total amount of enzyme introduced to the Encapsulator (see 
Section 2.1.1.1). For each preparation of a batch of microcapsules, the total amount of the 
enzyme (GOx) was obtained be measuring the flow rate and the time during which the 
encapsulation solution (GOx in aqueous sodium alginate) was poured into the calcium chloride 
bath. From this total amount of enzyme, inevitably, some of it is dispersed in calcium chloride 
bath once each small droplet reached the bath. Another portion of the enzyme diffused out of 
microcapsules in early stages of encapsulation process where the wall thickness of 
microcapsules was not thick enough to prevent the diffusion of enzyme molecules due to the 
time required for calcium ions to get incorporated into microcapsules’ wall network. Therefore, 
until the wall thickness reached its maximum, some of the enzyme passed through the pores of 
Figure 23. Histogram of microcapsules size distribution. 
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microcapsules’ wall. To determine the loss of enzyme in the calcium chloride bath, a Bradford 
protein assay was used to quantify the protein content of the bath. A typical calibration curve 
using BSA (bovine serum albumin) as the standard is shown in Figure 24. The amount of 
encapsulated enzyme was simply calculated by subtracting the amount of enzyme found in 
calcium chloride bath from the total amount of the enzyme introduced to the system. Using the 
aforementioned approach, the encapsulation efficiency was found to be 47 % in optimal 
conditions i.e. for a solution of GOx (0.5 mg/ml) in sodium alginate (7 % w/v) and formation of 
microcapsules in calcium ion bath (0.1 M)*.  
3.4. Chitosan modification  
Alginate, the main component in the structure of microcapsules, does not contain a 
significantly active functional group that can easily serve for further modification of 
microcapsules i.e. immobilization of antibody. That is why we decided to cover our 
microcapsules with a layer of chitosan. As described in Section 1.4.1, chitosan possesses amino 
                                                 
* The Data was obtained previously in Dr. Rochefort’s group by a summer intern. 
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Figure 24. A typical Bradford assay calibration curve using BSA as the standard. The 
concentration values refer to the total protein concentrations in spectrophotometric cell. 
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groups that can be protonated at acidic pH. Thus these amino groups carry positive charges 
which creates an ionotropic affinity for negatively charged carboxyl groups of alginate. Simple 
incubation of microcapsules in chitosan will form a layer of chitosan on the surface of alginate 
microcapsules. Another advantage of this extra layer is that the rigidity of microcapsules 
increases and they become more resistant in the presence of mechanical stress however, the 
porosity of microcapsules is reduced after the addition of chitosan layer67. 
To confirm a successful chitosan coverage of microcapsules, elemental analysis was 
carried out on empty alginate-chitosan microcapsules. The result of this analysis is given in 
Table 3. The presence of 0.54 % nitrogen is a confirmation of successful chitosan coverage 
because the only substance which contains nitrogen is chitosan because alginate does not have 
any nitrogen in its structure. 
Table 3. Elemental analysis result on alginate and alginate-chitosan microcapsules. 
To further confirm the coverage of alginate microcapsules by chitosan, it was suggested 
that chitosan be labeled with the fluorophore, fluorescein isothiocyanate (FITC). Therefore, 
chitosan was first derivatized with FITC and consequently used to cover alginate microcapsules. 
Apparently, despite FITC reacted the amino groups on the structure of chitosan, there existed 
some unreacted amino groups that could interact with alginate on the body of microcapsule.  
Both transmission and fluorescent images were taken using  confocal laser scanning microscopy 
(CLSM) (see Section 2.3.1.2.2) and the images are presented in Figure 25. The fluorescent 
signal from FITC-labeled chitosan in Figure 25b is a confirmation of the attained chitosan 
coverage. However, microcapsules appeared to be collapsed due to the mechanical pressure of 
the microscope slide cover. 
Sample Nitrogen (%w/w) Carbon (%w/w) Hydrogen (%w/w) 
Alginate microcapsules 0 40.91 4.54 
Alginate-chitosan 
microcapsules 0.54 29.07 4.75 
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3.5. Antibody immobilization 
To investigate the possibility of antibody immobilization on microcapsules, human 
immunoglobulin (IgG) was chosen as a model antibody with glutaraldehyde as the coupling 
agent as mentioned in Section 2.4.1. Keeping the concentration of calcium ion at 5 mM in these 
steps was needed to prevent the disassembly of microcapsules caused by the loss of calcium 
ions that bind the alginate chains together.  According to the literature, this amount of calcium 
ions is low enough not to reduce the immunoaffinity of IgG61.  
The immobilization of human IgG was tested using MALDI-TOF-MS. First, analysis was 
carried out on a sample of pure human IgG and the mass spectra is shown in Figure 26. Two 
characteristic peaks, one at ~150 kDa attributed to m/z of singly charged protonated IgG 
[M+H]+, and another one at ~75 kDa attributed to m/z of doubly protonated IgG [M+2H]2+ 
(Figure 26a). The very small peak observed at ~100 kDa remains unidentified. The same 
analysis on underivatized microcapsules shows a broad peak, typical for polysaccharides 
resulting from different polymeric chains of alginate with different lengths, which appear at 
many different and overlapping values of m/z (Figure 26b). The analysis of microcapsules with 
human IgG immobilized on their outer surface with MALDI-TOF-MS is shown in Figure 26c 
and depicted the presence of both characteristic peaks (the broad peaks for alginate and the pair 
of narrow peaks for the IgG) in the spectrum. It was quite important that MALDI-TOF-MS 
signal come from the antibody that is covalently attached to microcapsules and not those bound 
a) 
Figure 25. CLSM transmission images (a) and fluorescent images (b) of alginate microcapsules 
covered with FITC-labeled chitosan. 
b) 
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non-specifically via adsorption which could possibly give a false positive signal. To make sure 
of the absence of non-covalently bound antibody on the surface of microcapsules, a control 
sample experiment was carried out by omitting the linking agent (glutaraldehyde) from the 
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Figure 26. MALDI-TOF-MS spectra of human IgG (a), alginate microcapsules (b) 
and human IgG immobilized on alginate microcapsules (c). 
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immobilization reaction process. The obtained MALDI-TOF-MS spectrum was identical to that 
of bare microcapsules confirming that the antibody is attached covalently (results not shown).  
3.6. Activity measurements 
Our goal is to maintain the activity of the enzyme after encapsulation of GOx and also 
after each modification step. By definition, the activity of an enzyme in terms of a “Unit (U)” is 
defined as the µmoles of substrate consumed in one minute. “The specific activity” is defined 
as the activity of the enzyme in units per one gram of enzyme’s protein content, i.e. U/g. The 
activity measurements were carried out using the oxygen electro-analysis technique described 
in Section 2.6. So for each activity measurement, a certain amount of microcapsules was 
carefully weighed and transferred to the oxygen electrode cell. It was assumed that all our 
solutions were naturally saturated with oxygen, i.e. 284 µM at 25˚C . The solution in the cell 
was buffered with acetate buffer (50 mM, pH 5.0) and an excess amount of glucose (50 mg/ml) 
was added. The Clark-Cell electrode monitors the percentage of oxygen as a function of time. 
As predicted, the amount of oxygen stayed constant before the addition of glucose which is a 
proof that the signal is stable and also that the instrument works well. The oxygen content started 
to decrease after the addition of glucose and the initial slope of this curve, where the substrate 
(oxygen) existed in a high concentration, indicated the initial rate of the reaction. According to 
the notions explained in Section 1.5.3, the initial rate of the reaction has the maximum value of 
reaction rate that is also proportional to the concentration of the enzyme. The slope of the curve 
(% of oxygen versus time) stays constant as long as the reaction rate stays constant. This slope, 
which is in fact the	ୢሾ୓మ	%ሿୢ୲ 	, can easily be converted to the	
ୢሺஜ୫୭୪	୭୤	୥୪୳ୡ୭ୱୣሻ
ୢ୲  by knowing the 
stoichiometry of the reaction and also knowing the total amount of dissolved oxygen at 100 % 
of saturation at the temperature of the experiment as follows. According to the stoichiometry of 
the glucose oxidation reaction, the glucose to O2 ratio is 1:1; therefore, the enzymatic activity 
in terms of consumed µmoles of glucose is equal to that for µmoles of O2. Also knowing that at 
25˚C, the concentration of dissolved O2 in a saturated solution is 284 µM, the slope can be 
transformed in to the 	ୢሺஜ୫୭୪	୭୤	୓మሻୢ୲  as shown in Equation 13, where V is the total volume of the 
solution in the oxygen electrode cell in milliliters. A typical curve showing the rate of oxygen 
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consumption is given in Figure 27. Control experiments were conducted with empty 
microcapsules (i.e. without GOx) and no reduction in oxygen content was observed, confirming 
that the presence of GOx is needed to reduce the O2 content. 
Equation 13   ௗሺஜ௠௢௟	௢௙	ைమሻௗ௧ ൌ
ଶ଼ସ௏
ଵ଴଴଴ ൈ
ௗሺ%ைమሻ
ௗ௧  
To find the activity per gram of enzyme it was necessary to find out the total amount of 
the enzyme per unit of mass of microcapsules. In this regard, using the encapsulation efficiency, 
the total mass of encapsulated enzyme was divided by the total mass of obtained microcapsules 
in the same encapsulation batch. Performing the aforementioned method on five separate 
batches showed that with the applied encapsulation conditions, the amount of encapsulated 
enzyme is 0.82 ± 0.04 mg of enzyme per each gram of microcapsules.  
Figure 27. The oxygen content evolution in Clark-Cell oxygen electrode in the presence of 
alginate microcapsules. 
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The results of enzymatic activity measurements on free enzyme and on microcapsules 
after each modification step are given in Table 4. As can be seen, the enzymatic specific activity 
of GOx is reduced after its encapsulation in alginate microcapsules. This reduction can be due 
to the imprisonment of the enzyme in a confined space and being entangled in a network of 
alginate chains that possibly results in stabilizing certain conformations of the enzyme that are 
unfavorable for enzymatic activity. Moreover, once the enzyme is encapsulated, enzymatic 
activity is not merely dependent on the activity of the enzyme itself but also depends on the 
diffusion rate of the substrates (glucose and oxygen) through the microcapsule’s wall. The 
porosity and the thickness of the wall, as well as the density of the polymeric network inside the 
microcapsules are the factors that limit the accessibility of the substrates to the enzyme. All 
these unfavorable parameters have resulted in the reduction of enzymatic activity.  
Table 4. Activity measurements after each modification step on microcapsules. 
The second step of modification i.e. covering the microcapsules with chitosan also results 
in specific activity reduction. This event was also predictable since covering microcapsules with 
another layer will potentially decrease the porosity of the wall which as mentioned before could 
result in a lower diffusion rate for substrates. It was imagined that incubation of microcapsules 
overnight in a solution of chitosan may be accompanied by the gradual leaching of the enzyme 
out of microcapsules. So the incubation solution was assessed for protein by the Bradford 
method. The results did not show a significant leaching out of enzyme that could be detectable 
by Bradford method. Therefore, it was assumed that after the formation of microcapsules in 
Sample Specific Activity  ( U/ gprotein) 
Free GOx enzyme (5.3±0.1)×104 
Encapsulated GOx in microcapsules (4.3±0.3)×102 
Encapsulated GOx in chitosan-modified microcapsules (1.3±0.2)×102 
Encapsulated GOx in chitosan-modified microcapsules after 
antibody immobilization (1.2±0.3)×102 
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calcium chloride bath and incubation for at least 30 minutes, the microcapsule’s wall becomes 
thick enough not to let the enzyme escape away from microcapsules.  
After the last modification step (i.e. immobilization of an antibody on microcapsules), it 
was expected that a decrease in enzymatic activity might be observable, which can be explained 
by two possible sources. One is the addition of another complex layer of biomolecules on the 
surface of microcapsules and another source is the use of glutaraldehyde during the 
immobilization step. As a small but highly reactive molecule, some glutaraldehyde can possibly 
diffuse into microcapsules and crosslink or handcuff the enzyme in some ways. But the 
reduction in enzymatic activity was observed to be really small and below the confidence 
interval of the measurement since a relatively low concentration of glutaraldehyde (0.25 % w/v) 
is used. Also, the amino groups on the surface of the microcapsules are more accessible for 
glutaraldehyde to react with rather than the enzyme inside microcapsules. It is also possible that 
the glutaraldehyde could crosslink chitosan, making it less porous to glucose. 
3.7. Summary 
In this chapter, it was demonstrated that GOx can be encapsulated in alginate 
microcapsules. Also the surface of such microcapsules can be functionalized and covered with 
an extra layer of chitosan to increase the mechanical stability of the capsules and to add amino 
groups required to subsequently link antibodies on the capsules. A successful immobilization of 
human IgG as a model antibody was confirmed by MALDI-TOF-MS. The enzymatic activity 
of GOx was measured after each step and the results showed that the enzyme have maintained 
its activity during the preparation of our designed platform. 
 
 
 
Chapter 4. Bacterial growth inhibition 
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4.1. General objectives 
The next step of our study, after the preparation and characterization of the proposed 
antibacterial platform consisted in the evaluation of the antibacterial properties of the 
microcapsules. Therefore, in the present chapter, the effect of the enzymatic activity (originated 
from encapsulated GOx in alginate microcapsules) on the growth of E. coli K-12, our model 
bacteria, is studied. Also the results and discussion of the inhibition of bacterial growth are 
brought to the attention of the readers.  
4.2. Inhibition of bacterial growth in a petri dish 
In preliminary studies, to evaluate the antibacterial properties of microcapsules containing 
GOx, 1.007 g of microcapsules containing GOx were spread on a sterilized paper disc (d=1.6 
cm) and placed at the central spot of a petri dish containing sterilized LB broth culture media 
with 2 % agar gel, 10 % glucose and a carpet of E. coli K-12 on top of the culture media (see 
Section 2.7.1) . For the control sample, 1.007 g of empty microcapsules (without GOx) were 
used on the central paper disc. In general, in the absence of any antibacterial activity, the bacteria 
will grow on the petri dish and as the result of the bacterial growth the culture media becomes 
turbid due to the optical density of the bacteria. In the presence of an antibacterial agent in any 
region on the petri dish, no bacterial growth near the region of antibacterial activity will occur 
thus, no turbid area is observable, which means the culture media stays transparent. In our 
experiment, after 16 hours of incubation at 37˚C, both petri dishes were observed visually to see 
the possible bacterial growth inhibition. The result is shown in Figure 28 and as can be seen, on 
petri dish with microcapsules containing GOx (Figure 28-right), a transparent halo had appeared 
around the paper disc showing that the bacteria was inhibited to grow in the region where there 
was some GOx. Apparently glucose (present in the culture media) was able to diffuse into 
microcapsules where it is engaged in the oxidation reaction thus producing some hydrogen 
peroxide that could diffuse away from the microcapsules. This amount of hydrogen peroxide 
was enough to prevent the bacterial growth in the vicinity of treated paper disc. While for the 
control experiment (Figure 28-left), since there was no GOx in the system and therefore no 
hydrogen peroxide production occurring, the bacteria were able to grow freely. 
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4.3. Growth inhibition threshold 
For further understanding of the antibacterial activity of our designed microcapsule-based 
platform we decided to analyze the inhibition of bacterial growth at a scale larger than a petri 
dish. Therefore, the growth inhibition was studied by monitoring the optical density of E. coli 
K-12 at 600 nm approximately once every 30 min during a time window of 24 hours. In this 
regard microcapsules containing GOx (providing a known amount of enzymatic activity) were 
added to the LB broth culture media according to the procedure described in Section 2.7.2.  
Since hydrogen peroxide is the antibacterial agent in our system and it is produced 
gradually in the media and on the other hand E. coli growth is a dynamic process of living cells, 
in presence of some enzymatic activity, the bacterial growth is assumed to be a function of 
different factors. The bacteria are growing while consuming the glucose as a nutrient, and on 
the opposite side while the enzyme is still active, we will have a constant consumption of glucose 
and a constant production of hydrogen peroxide which is then consumed to decompose the 
bacteria. Since the bacteria are living cells, they are trying to grow; therefore, at each certain 
time-point the total population of the bacteria is a function of their growth rate and their 
decomposition rate.  
Figure 28. Bacterial Growth inhibition on petri dish with microcapsules containing glucose 
oxidase (right) and microcapsules without glucose oxidase (left) applied to a 2 cm2 paper 
disc placed at the centre of the petri dish. 
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It was obviously assumed that there would be a threshold for the amount of enzymatic 
activity in the system that can effectively inhibit the bacterial growth of a certain initial number 
of bacteria. To find the optimized enzymatic activity or in other words, to find the threshold 
which can also be defined as the “optimal effective enzymatic activity”, different concentrations 
(as U/ml) of free GOx were tested while keeping the initial concentration of E. coli cells 
constant. In a set of parallel experiments, 100 µl of a saturated solution of E. coli K-12 
(previously cultivated in LB broth culture media and incubated in 37˚C for 16 hours) was added 
to LB broth culture media through the experimental set up and conditions as described in Section 
2.7.2.3. Knowing that the saturated cellular concentration of E. coli in LB broth culture media 
is approximately 6.7×109 cells/ml66, the 100 µl amount of bacteria in our experiment provides 
6.7×108 cells/ml of E. coli. The enzymatic activity was created by adding GOx ranging from 0 
to 1.9×10-2 U/ml in different culture batches while keeping the initial amount of bacteria 
constant. The bacterial growth in all batches was observed and plotted as shown in Figure 29. 
Figure 29. Effective enzymatic activity threshold inhibiting bacterial growth for six different 
concentrations (in U/ml) of free GOx. 
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 The sample containing 0 U/ml, is considered as the control sample which demonstrate the 
normal growth of E. coli. and reached the stationary phase of bacteria’s life cycle in about 4.8 
hours after the incubation at 37˚C. As can be seen in Figure 29, normal bacterial growth 
exponential phase faces a difficulty to initiate and therefore a relatively large lag phase was 
observed in presence of enzymatic activity or more precisely, the production of hydrogen 
peroxide in culture media. Consequently, at 0.9×10-2 U/ml of free GOx, the stationary phase 
was attained after approximately 6.5 hours. Similarly, 1.1×10-2 U/ml of free GOx activity will 
delay the growth even more and the stationary phase appeared 7.5 hours after the start of 
incubation. Surprisingly, at 1.3×10-2 U/ml the bacteria had a real problem for growth and with 
a relatively large delay (in comparison with lower amounts of enzymatic activity in the culture 
media), the stationary phase appeared after 12 hours of incubation. For the samples containing 
higher enzymatic activity i.e. for the samples containing 1.5×10-2, 1.7×10-2 and 1.9×10-2 U/ml 
no growth was observed which means apparently the bacteria’s decomposition rate is larger than 
their growth rate. In this case either the bacteria decomposed totally at earlier stages or the 
population is kept so low that it could not enter the exponential growth phase.  Therefore, 
1.3×10-2 U/ml was considered as the maximum enzymatic activity that E. coli K-12 could 
tolerate and grow, although with relative difficulty.  
Moreover, besides exerting a lag in bacterial growth, the presence of enzyme with a certain 
activity was observed to have an adverse effect on the growth rate during the exponential growth 
phase of the bacteria’s life cycle. To evaluate this, the slope of growth was calculated by linear 
regression for each exponential growth phase and the trend lines are presented in Figure 30. As 
can be seen from the slopes, the rate of growth is another factor that can be affected by the 
presence of some enzymatic activity in the culture media. With an increase in the enzymatic 
GOx activity from 0 to 1.3×10-2 U/ml, the slope decreases consequently showing that the 
decomposition rate exceeds the growth rate accordingly.  
To summarize this part of the study, we can conclude that the presence of enzymatic 
activity on bacterial growth showed a total inhibition effect for concentrations of GOx 
corresponding to activity of more than 1.3×10-2 U/ml and also showed a delaying effect that 
increased with GOx. This delay on the time the bacteria’s life cycle reaches its stationary state 
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was observed to be partly as a result of elongation in the bacteria’s lag phase and also as a 
decrease in the slope of the exponential growth phase. It should be mentioned that the optical 
densities of the culture media for all batches were checked after 24 hours and the condition of 
all samples had stayed the same as what had been measured after 12 hours. 
To check the reproducibility of the system and also to see if our antibacterial 
microcapsules behave in the same manner as free enzyme, the following four different samples 
(each repeated in triplicate) were prepared and analyzed: i) a control sample with zero enzymatic 
activity i.e. no free GOx; ii) a sample containing 1.3×10-2 U/ml generating from free GOx; iii) 
a sample containing 1.3×10-2 U/ml generating from our antibacterial microcapsules; and iv) a 
sample containing 1.9×10-2 U/ml generating from our antibacterial microcapsules. All twelve 
samples were incubated with E. coli K-12 under the same conditions as previously mentioned 
in the current section.  The result of optical density monitoring at different time points for all 
four samples including their error bars (SD, n=3) are presented in Figure 31. As was expected 
for the first sample, normal growth was observed because no enzymatic activity and thus no 
Figure 30. Linear regression of the exponential growth phase from the graphs in Figure 29 for 
free GOx. 
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hydrogen peroxide was present to meddle with bacterial growth. The bacteria in the second 
sample (containing free GOx with enzymatic activity equal to the determined threshold) 
succeeded to grow after approximately 12 hours. Although the third sample contained the 
threshold amount of enzymatic activity, the encapsulated enzyme showed slightly less inhibition 
than the free enzyme for the equivalent enzymatic activity. Such behavior could be possibly due 
to the imperfection of experimental conditions. It was observed that through the incubation and 
strong agitation of the incubation vessel (an Erlenmeyer), some of the microcapsules adhere to 
the inner wall of the vessel therefore these microcapsules may not contribute to the total 
enzymatic activity of the solution. For the forth series of samples containing encapsulated GOx 
at 1.9×10-2 U/ml, since the enzymatic activity in the culture media is higher than the threshold 
determined in Figure 29 for inhibition, no bacterial growth was observed, as expected. Also, 
and the adhesion of microcapsules to the inner wall of the vessel, is not effective enough to 
reduce the enzymatic activity inside the solution to a level below threshold. Thus, our designed 
microcapsules have depicted the expected antibacterial properties above the aforementioned 
threshold.  
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Another step for optimizing the bacterial growth inhibition is to find the initial number of 
bacteria that could not grow in the presence of a certain level of enzymatic activity and thus the 
generated hydrogen peroxide. Therefore, in another series of experiments, the enzymatic activity 
was kept at constant value of 1.9×10-2 U/ml and different initial amounts of E. coli K-12 ranging 
from 0.67×109 to 3.0×109 cells/ml were tested for growth. The results, which are given in Figure 
32 demonstrate that a population of 0.67×109 cells/ml E. coli bacteria sample could not grow in 
the presence of 19 mU/ml GOx whereas a larger initial population were able to grow. However, 
a relative delay in bacterial growth was observed proportional to the initial amount of the 
bacteria. 
4.4. Summary 
In this chapter, the antibacterial properties of our designed platform was verified against 
E. coli K-12 as a model pathogen. Preliminarily, a successful inhibition of bacterial growth was 
observed in a petri dish. furthermore, the detail of this bacterial growth inhibition was studied 
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1.9×10-2 U/ml enzymatic activity. 
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by monitoring the optical density of the culture media which represented the number of bacteria 
at different time points of bacterial growth. In this regard a threshold of enzymatic activity in 
the media was found to be effective to prevent certain initial amount of bacteria from growing. 
Similarly, the minimum initial amount of bacteria that could grow at certain amount of 
enzymatic activity was also determined. 
 
 
 
 
Chapter 5. Immobilization of glucose oxidase on gold 
nanoparticles
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5.1. General objectives 
Since the encapsulation of GOx in alginate microcapsules results in reduction of its 
activity and losses in enzyme during the encapsulation procedure (see Section 3.6), we evaluated 
the immobilization of the GOx on gold NPs prior to its encapsulation. Our hypothesis is that 
enzyme immobilization on gold NPs could possibly increase the enzymatic activity and 
potentially compensate the activity loss in the microcapsules. This idea is based on the 
assumption that immobilization of enzyme molecules on massive gold NPs could possibly 
reduce the mobility of the enzyme and thus could reduce the diffusion of the enzyme at early 
stages of encapsulation while the thickness of the microcapsules’ wall is not large enough to 
prevent the loss of enzyme in the calcium chloride bath. Another advantage could be an increase 
in the enzyme’s shelf life and thermostability that can be considered as an asset in preparation 
of a durable antibacterial paper that maintains its properties on larger time scales as well as being 
operative in wider range of temperatures. 
5.2. Introduction 
Recently, metal NPs, especially gold NPs, have played an extensive role in biochemistry 
and biomedical research because of their high reactivity to living cells (in terms of translocation 
into the cells) , their large surface area to volume ratio, their various sizes and shapes and most 
importantly their stability at high temperatures68. In comparison with other metals, gold NPs are 
most preferable for applications such as drug and gene delivery, due to their inertness and lower 
cytotoxicity. All these applications are feasible through a bioconjugation process in which 
biomolecules are attached to gold NPs via a bifunctional ligand68. In the case of GOx, a 
bioconjugation method was proposed in which gold NPs are functionalized by carboxyl 
terminated thiol groups (HS—R—COOH) i.e. using mercaptoundecanoic acid (MUA). It has 
also been shown that thermostability of the enzyme is enhanced once it is immobilized on gold 
NPs (d=20 nm)69. Meanwhile, another study showed the same immobilization process of GOx 
on gold NPs (d=5 nm) will enhance the  enzymatic activity greatly as well as its shelf life70. The 
same study showed a lower value of Michealis-Menten constant (Km) for the immobilized 
enzyme compared to that of the free enzyme and an enhancement of 1.56-fold in the enzymatic 
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affinity was found. The enhancement in thermostability of GOx was also shown using 
bioconjugation of this enzyme on gold nanorods71. However, a very recent study yielded 
completely different results, showing that the immobilization of GOx on gold NPs (d=37 nm) 
has an adverse effect on enzymatic activity. This decrease was explained by a decrease in the 
percentage of the enzyme’s α-helix conformation, which contributes to its enzymatic activity 
once it is attached to the surface of gold NPs. It seems that the closer to the surface of the 
nanoparticle the enzyme is, the lower the activity becomes72.  
5.3. Methods 
5.3.1. Preparation of thiol-modified gold nanoparticles 
The synthesis of gold NPs was carried out using the conventional Turkevich method73 
which includes the reduction of hydrogen tetrachloroaurate (III) (HAuCl4.3H2O, Sigma-
Aldrich) using trisodium citrate dihydrate (Sigma-Aldrich) through reaction presented in 
Equation 14 and heating the solution to the boiling point. Citrate ions also act as the stabilizing 
agent for gold NPs which prevents them from forming aggregates. All glassware was rinsed 
with Aqua Regia (a 1:3-mixture of nitric acid and hydrochloric acid) followed by rinsing with 
MilliQ water to remove all traces of metallic contaminations. These NPs were then incubated 
overnight in a solution of MUA in ethanol to undergo a process of ligand exchange during which 
citrate is replaced with MUA to give thiol-modified gold NPs for further reactions. NPs were 
removed from the solution by centrifugation followed by several washes with ethanol and re-
dispersion in phosphate buffer (10mM, pH 6.8 with 0.2 mg/ml Tween-20). 
Equation 14 2	ܪܣݑܥ݈ସ 	൅ 	4	ܰܽଷܥଷܪହܱ଻ → ܪଶ ൅ 2	ܣݑ଴ ൅ 4	ܥܱଶ ൅ 4	ܰܽܥହܪହܱହ ൅ 8	ܰܽܥ݈ 
5.3.2. Immobilization of glucose oxidase on gold nanoparticles 
Immobilization of GOx on thiol-modified gold NPs was carried out based on a coupling 
reaction using N-ethyl-N’-(3-dimethylaminopropyl) carbodiimide (EDC) activation and N-
hydroxy-succinimide (NHS). A summary of the whole process is schematically illustrated in 
Figure 33 69. A sample of 1.0 mg of the NPs were reacted with a freshly prepared solution of 50 
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mM NHS and 200mM EDC for 10 min. Then, NHS-terminated gold NPs were separated from 
the reaction solution by centrifugation (at 8000 rpm for 10 min) and washed with phosphate 
buffer (10 mM, pH 6.8, with 0.2 mg/ml Tween-20) several times. The NHS-terminated gold 
NPs were then incubated with 0.8 mg/ml GOx in phosphate buffer (10 mM, pH 6.8) overnight 
under argon atmosphere. The mixture was then centrifuged to discard free GOx which remains 
in the supernatant and washed by phosphate buffer, and re-dispersed in the same buffer for 
further analysis. The detail of this series of reactions is given in Figure 34. 
Figure 33. Schematic illustration of enzyme immobilization on gold nanoparticles 
(adapted from reference 69). 
Glucose oxidase 
Figure 34. Mechanism of the reactions resulting in immobilization of glucose oxidase on 
thiol-modified gold nanoparticles. 
69 
 
 
 
5.4. Enzymatic activity measurements 
Several attempts were made to measure the enzymatic activity of GOx immobilized on 
gold NPs using the oxygen electroanalysis method described in Section 2.6.1. This method was 
found to be practically impossible as a result of the strong aggregation of NPs observed in the 
Clark-Cell and also due to relatively low sensitivity of this technique. We therefore, used the 
spectrophotometric method of horseradish peroxidase (HRP) and its substrate, 3,3′-
dimethoxybenzidine (o-dianisidine). In this method, glucose is oxidized in the presence of GOx 
which produces hydrogen peroxide (Equation 1). Then, hydrogen peroxide is used rapidly to 
oxidize o-dianisidine through an enzymatically catalyzed reaction using HRP to form the 
oxidized dimer form of o-dianisidine which absorbs visible light at λmax= 455 nm, as shown in 
Equation 15. The details of this reaction are schematically illustrated in Figure 3574. Typically, 
to measure the enzymatic activity, 2.5 ml of a solution of 0.33mM of o-dianisidine in phosphate 
buffer (0.1 M pH 6.8), 0.1 ml of a solution of 0.02 % HRP and 0.3 ml of 18 % glucose solution 
were mixed in a spectrophotometric cell and then a certain amount of GOx bound to gold NPs 
solution was added and the absorbance evolution was observed as a function of time at 455 nm. 
Equation 15 ܪଶܱଶ ൅ ݋ െ ݀݅ܽ݊݅ݏ݅݀݅݊݁	ሺݎ݁݀ݑܿ݁݀ሻ → ܪଶܱ ൅ 	݋ െ ݀݅ܽ݊݅ݏ݅݀݅݊݁	ሺ݋ݔ݅݀݅ݖ݁݀ሻ 
Figure 35. The reaction scheme of peroxidase oxidation of o-dianisidine (reproduced from 
reference 74). 
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To calculate the enzymatic activity, after plotting the evolution of absorbance (A) versus 
time as shown in Figure 36, the slope of the linear part of the curve (at early stages of the 
reaction) is determined which corresponds to the enzymatic activity of GOx as follows: the slope 
of the curve corresponds to ೩ಲ೚ష೏೔ೌ	ሺ೚ೣሻ೩೟ 	ሺ௠௜௡షభሻ, knowing that ε, the extinction coefficient for the 
oxidized form of o-dianisidine at 455 nm equals to 11300 (M-1cm-1)75 and the thickness of the 
spectrophotometric cell which represents the light path (b) equals 1 cm, on the basis of the Beer-
Lambert law (A= ε.b.C) the slope can easily be converted to ೩ሾ೚ష೏೔ೌ	ሺ೚ೣሻሿ೩೟ 	ሺெ	௠௜௡షభሻ and by taking 
the stoichiometry of the reactions into consideration (Equation 1 and Equation 15), we can 
conclude that: 
Equation 16  ೩ሾ೚ష೏೔ೌ	ሺ೚ೣሻሿ೩೟ 	ሺெ	௠௜௡షభሻୀି
೩ሾಹమೀమሿ
೩೟ 	ሺெ	௠௜௡షభሻୀష
೩ሾ೒೗ೠ೎೚ೞ೐ሿ
೩೟ 	ሺಾ	೘೔೙షభሻ  
And since the total volume of the solutions in the spectrophotometric cell, V(ml) is also a known 
parameter, therefore, the enzymatic activity can be determined from Equation 17 as follows:   
Equation 17 Enzymatic activity (µmoles of glucose/min) ൌ ௏௱ሾ௚௟௨௖௢௦௘ሿଵ଴଴଴௱௧ ൌ
௱ሾஜ	௠௢௟௘௦	௢௙	௚௟௨௖௢௦௘ሿ
௱௧   
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Figure 36. Enzymatic activity measurement in HRP/o-dianisidine- a sample plot. 
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5.5. Results and discussion 
5.5.1. Preparation of gold nanoparticles  
In our study, two sets of gold NPs having different sizes were tested for the GOx 
immobilization. The first set of gold NPs had an average diameter of 10.9±1.8 nm (Figure 37). 
The average diameter and size distribution for these gold NPs (Figure 39) that were prepared 
using the method described in Section 5.3.1 were determined using transmission electron 
microscopy (TEM). The UV-Vis extinction spectra is also provided in Figure 38. The other set 
was gold NPs of ~50 nm in diameter. The approximate diameter of these NPs was determined 
from its UV-Vis extinction spectra by finding the ratio of its absorbance value at λSPR to the 
absorbance value at 450 nm and by comparing the calculated ratio with the values mentioned in 
the literature. This method of size determination was developed by Haiss et al.76 in 2007. The 
UV-Vis extinction spectra (Figure 40) of such NPs was obtained and the ratio A527nm/A450nm 
yields the value equal to 2.03 which determines the average diameter of 50 nm for this sample 
of gold NPs.  
Figure 37. TEM image of gold NPs of d=10.9 nm. 
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Figure 39. Histogram of gold NPs’ size distribution with average diameter equal to 10.9 nm 
as determined by TEM image treatment. 
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Figure 38. UV-Vis extinction spectra of gold NPs (d=10.9 nm) and GOx-immobilized-gold 
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Gold NPs with an average diameter of 10.9 nm were prepared according to the method 
explained in Section 5.3.1 and a batch of gold NPs with an average diameter of 50 nm was 
provided by Dr. Jean-François Masson’s research laboratories at Université de Montréal. After 
functionalizing these two sets of gold NPs with MUA, we used them for GOx immobilization. 
To be able to calculate the enzymatic activity, it was necessary to determine the amount of 
enzyme that could possibly be immobilized on gold NPs. For this, a Bradford protein assay was 
used to analyze the enzyme solution before and after the incubation step with the NPs. After the 
incubation and centrifugation steps, samples were taken from the supernatant for quantification 
of the amount of the enzyme which stayed unreacted and free in the solution. It is evident that 
the difference of those two amount indicate the amount of immobilized enzyme on NPs (the 
results are presented and discussed in Sections 5.5.2 and 5.5.3). The NPs were then redispersed 
in phosphate buffer (10 mM, pH 5.8) for storage at 4˚C. These NPs were consequently observed 
by TEM, their zeta potential (ξ) was measured and their enzymatic activity was determined 
using HRP/o-dianisidine spectrophotometric method. 
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Figure 40. UV-Vis extinction spectra of gold NPs (d≈50 nm) and GOx-immobilized-gold 
NPs(d≈50 nm). The absorbance values are normalized to the value of the maximun 
absorbance of each curve. 
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5.5.2. Immobilization of glucose oxidase on gold nanoparticles with average 
diameter of 10.9 nm 
In the enzyme immobilization process, three samples of gold NPs (d=10.9 nm) were tested 
including a control sample for which the linking reactants (EDC/NHS) were eliminated to see 
if the enzyme could be physically adsorbed on the surface of gold NPs. The details of these 
samples are given in Table 5 along with the amount of the enzyme immobilized as determined 
by performing the Bradford protein assay on the enzyme solution before and after incubation 
with gold NPs. Although it could be expected that a sample with more NPs provides more 
surface available for the enzyme to be immobilized, it was observed that lower amounts of 
protein were immobilized. This observation suggests that a single enzyme molecule is possibly 
attached to more than one nanoparticle when high concentrations of NPs were used in the 
incubation step. As we will see, this results in a deactivation of the enzyme. 
Table 5. Immobilized enzyme content on gold NPs of d=10.9 nm. 
The results from activity measurements, which were obtained using HRP/o-dianisidine 
spectrophotometric method are given in Table 6. Surprisingly, a very low specific activity was 
observed for the enzyme immobilized on gold NPs of d=10.9 nm compared to free enzyme. 
Moreover, the specific activity (U/g of protein) for the sample using larger amount of NPs was 
higher than that of the sample with smaller amount of NPs. Regardless of this difference in 
specific activity, both of these two values are very much lower than the activity of free enzyme. 
One possible explanation for this observation could be the denaturation of the enzyme during 
Sample 
Description 
Enzyme content in solution (mg), n=3 Total 
immobilized  
enzyme (mg) 
Efficiency 
(%) Before incubation  After incubation  
1  0.46 mg of gold NPs 18.16±0.06 17.19±0.02 1.01±0.08 5.6±0.5 
2  0.10 mg of gold NPs 15.84±0.04 9.44±0.02 6.42±0.06 40.5±0.5 
3  0.10 mg of gold NPs  Control without EDC/NHS 17.01±0.02 17.03±0.02 - - 
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the immobilization process. The favorable conformation for the enzymatic activity of GOx 
could undergo certain changes that may have resulted in a reduction in enzymatic activity. 
Another possible explanation could be based on the proximity of the size of  GOx (d=4.3 nm)77 
to the size of NPs (d= 10.9 nm). Since the enzyme’s size is close to the nanoparticle’s size, there 
is a chance of having a very few number of immobilized enzyme per a single nanoparticle. Also 
there is a possibility that a single enzyme attaches to two or more NPs, exerting some unwanted 
interactions that may alter the favorable conformation of the enzyme which ends up in a decrease 
in enzymatic activity. This hypothesis is also justified by studying the UV-Vis spectra of gold 
NPs before and after immobilization of GOx. As can be seen in Figure 38, the λSPR of gold NPs 
shifted to larger wavelengths and this redshift of 58 nm is accompanied by the λSPR peak 
broadening which can be a proof to the fact that the immobilization of the enzyme resulted in 
coalescence of gold NPs. The coalescence of gold NPs creates agglomerations of particles with 
different sizes whose size distribution contributes to the λSPR peak broadening. In fact, by 
attaching to two or more particles, the enzyme could act as a chemical glue for the gold NPs. In 
order to evaluate these possibilities, another sample of gold NPs with a larger size was used to 
carry out the immobilization. 
Table 6. Enzymatic activity measurements for free glucose oxidase and different nanoparticle 
samples of d=10.9 nm. 
Sample Description Specific enzymatic activity  (U/g of protein), n=3 
0 Free GOx (13.2±0.2)×104 
1  0.46 mg of gold NPs (8.1±0.5)×101 
2  0.10 mg of gold NPs 7.4±0.3 
3  0.10 mg of gold NPs  Control without EDC/NHS No activity observed 
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5.5.3. Immobilization of glucose oxidase on gold nanoparticles with average 
diameter of ≈50 nm 
A set of three samples was prepared and tested with these gold NPs and the amount of the 
enzyme immobilized in each sample was determined by performing the Bradford protein assay 
on the enzyme solution before and after incubation of gold NPs (Table 7). Similar to the previous 
set, for the sample with more NPs in incubation step, it was observed that smaller amount of 
protein was immobilized comparing to the sample with smaller quantity of NPs. As previously 
observed in the study GOx immobilization on smaller gold NPs (Section 5.5.2), here again the 
idea that a single enzyme molecule can possibly attach to more than one NP  and thus, possible 
coalescence of NPs could be suggested. However, the amount of coalescence is not as large as 
in the case of smaller gold NPs because the UV-Vis extinction spectra of such gold NPs  in 
Figure 40 (after immobilization of GOx) does not show a significant redshift or peak broadening 
in comparison with that of the gold NPs of d=10.9 nm (Figure 38) . No significant differences 
in protein content was found before and after incubation for the sample without using EDC/NHS 
showing that the enzyme was not immobilized without anchoring group. 
Table 7. Immobilized enzyme content on gold NPs of d≈50 nm. 
The results of the activity measurements for these three samples are given in Table 8. As 
can be seen, sample 1 which has higher amount of NPs (and also contains smaller amount of 
immobilized enzyme) shows a significant value of specific enzymatic activity comparing to 
sample 2 that has smaller amount of NPs (and also contains more immobilized enzyme). Also 
in comparison with sample 1 of the previous set in Section 5.5.2 (that contains same mass of 
Sample 
Description 
Enzyme content in solution (mg), n=3 Total 
immobilized  
enzyme (mg) 
Efficiency 
(%) 
Before incubation  After incubation 
1  0.46 mg of gold NPs 17.24±0.05 16.27±0.03 0.97±0.08 5.6±0.5 
2  0.10 mg of gold NPs 14.45±0.05 10.30±0.04 4.15±0.09 28.7±0.7 
3  0.10 mg of gold NPs  Control without EDC/NHS 16.64±0.03 16.68±0.07 - - 
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NPs with smaller size), this sample exhibits a larger value of enzymatic activity. This 
observation suggests that greater coalescence phenomenon occurs in case of immobilization of 
GOx on smaller gold NPs. A higher coalescence results in a lower enzymatic activity due to the 
smaller diffusion rate of substrate to the active sites of the enzyme when the aggregation of NPs 
happens. But regardless of such an improved activity by just increasing the size of gold NPs, 
there is still a big difference between the activity of free enzyme and immobilized enzyme which 
is totally unfavorable to our need. Possibly in certain cases, the enhanced thermostability and 
increased shelf life of the GOx after immobilization on gold NPs (as stated in previous studies69-
71) could be tempting to use this combination (nanoparticle-enzyme) in the encapsulation 
process. For sample 3 (the control sample without using reagents EDC/NHS in incubation step), 
no significant enzymatic activity was observed. Further details on the properties of gold NPs 
after the modification steps are required to understand the changes in the NPs’ surface. 
Table 8. Enzymatic activity measurements for free glucose oxidase and different nanoparticle 
samples of d≈50 nm. 
The effect of immobilization of GOx on a wavelength which corresponds to the NPs’ 
Surface Plasmon Resonance (SPR) was also observable in UV-Vis extinction spectra of NPs 
after the immobilization step. As can be seen in Figure 40 the λSPR of gold NPs undergoes a red 
shift of 12 nm comparing to the λSPR of gold NPs stabilized by citrate and is one of the proofs 
that the chemistry of the surface of gold NPs have changed.  
Sample Description Specific enzymatic activity  (U/g of protein), n=3 
0 Free GOx (13.2±0.2)×104 
1  0.46 mg of gold NPs  Normal reaction conditions (11.2±0.3)×102 
2  0.10 mg of gold NPs  Normal reaction conditions (17.7±0.6)×101 
3  0.10 mg of gold NPs  Reaction without EDC/NHS No activity observed 
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Imaging of gold NPs covered with MUA and GOx immobilized-gold NPs (Figure 41(a) 
and (b) respectively) were acquired using transmission electronic microscopy (TEM). As can be 
seen in Figure 41(b) , a semi-transparent layer of the enzyme covers the NPs which forms 
structures known as the “fried egg”. For further confirmation of the presence of the enzyme 
attached to NPs, a few drops of silver nitrate (1 % w/v) had been added to the TEM grid in both 
images in  Figure 41 and as the result of reduction of silver ions to Ag0 by oxidative amino acids 
present in the protein, tiny NPs of silver are formed in areas which the enzyme exists unlike for 
the grid containing gold NPs with MUA in Figure 41(a). These Ag NPs are more visible in 
Figure 42(a), which is a magnified image of Figure 41(b) and the energy-dispersive X-ray 
Figure 41. TEM images of gold nanoparticles with MUA (a) and  gold nanoparticles with 
immobilized glucose oxidase (b). 
(a)                                                                (b) 
Magnified zone  
Figure 42. Magnified TEM image of glucose oxidase- immobilized gold nanoparticles (a) and 
EDS of the specified region (b) . 
EDS 
   (a)                                                   (b) 
79 
 
 
 
spectra (EDS) of the specified region on the photo is presented in Figure 42(b) confirming the 
presence of silver element around each gold NPs which gives a peak at ~3KeV in the spectra. It 
should be noted that the addition of silver nitrate solution on conventional copper-made TEM 
grids was impossible due to the oxidation and therefore corrosion of copper grids by silver ions. 
So in order to prevent this, we had to use TEM grids made of gold. 
Another way to follow the surface modification of gold NPs is to measure the zeta 
potential (ξ) of these particles. The zeta potential for this set of gold NPs were also measured 
and in a DTS1070 disposable capillary cell using a Malvern Zetasizer Nano ZS instrument and 
the results are given in Table 9. The zeta potential is a parameter which shows how strongly 
ions of opposite charge are bound to the charged surface to form a charged layer. This layer of 
ions with opposite charge plays an important role to stabilize gold NPs in the solution and 
prevent them from aggregation and therefore precipitation because a strongly-bound charged 
layer will repulse other particles with the same charge and that is why the particles could never 
get close enough to each other to form a larger aggregate of solid that could precipitate.  
Table 9. Zeta potential measurements of different gold NPs samples of d≈50 nm. 
In our case it was observed that gold NPs covered with MUA have a zeta potential value 
of -35.9 mV, which explains a relative stability of these gold NPs in a solution at pH 5.8 (10 
mM phosphate, pH 6.8, 0.2 mg/ml Tween-20) compared to the samples with immobilized GOx. 
This stability results from the carboxyl group at the end of MUA which covers the NPs. This 
Sample Description Zeta potential (mV) (n=3) 
0 Gold NPs-MUA (in phosphate 10mM, pH 6.8, 0.2 mg/ml Tween-20) -35.9±0.1 
1 Gold NPs-enzyme (in phosphate 10mM, pH 5.8)  Immobilization conditions: 
 0.46 mg of gold NPs 
-4.0±0.9 
2 Gold NPs-enzyme (in phosphate 10mM, pH 5.8)  Immobilization conditions: 
 0.10 mg of gold NPs 
-5.6±0.9 
3 Gold NPs-enzyme (in phosphate 10mM, pH 5.8)  Immobilization conditions: 
 0.10 mg of gold NPs (Control without EDC/NHS) 
-9.4±0.9 
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carboxylic acid is a highly polar functional group and also dissociable to form carboxylate ion 
which is negatively charged. Another reason for this large value of zeta potential was the use of 
Tween-20 as a non-ionic surfactant which creates extra stability69. After the immobilization of 
the enzyme on gold NPs the zeta potential decreases to values close to zero. Such a low value 
for zeta potential could be another factor for a decrease in enzymatic activity. Since the particles 
have low stability in solution and they tend to form aggregates, the active site of the enzyme 
may not be easily accessible for the substrates and also the slow diffusion of the substrate on the 
aggregates could result in a decrease in enzymatic activity of GOx.  
To study the effect of zeta potential on enzymatic activity, it was suggested that we first 
increase the stability of NPs. Since we were dealing with an enzyme, the use of Tween-20 as a 
non-ionic surfactant was not recommended since it may alter the activity of the enzyme directly 
by stabilizing certain conformations. Another choice was to increase the pH to increase the 
negative charge on GOx (knowing that the isoelectric point of this enzyme is 4.278). According 
to the targeted application of these gold NPs, which is to use them in the encapsulation process, 
the maximum pH that can be reached is at pH 7.0 since calcium ions could potentially produce 
precipitation of calcium hydroxide at alkaline pH values. Another set of NPs was prepared using 
the same conditions as sample 1 in the previous set (0.46 mg of gold NPs incubated with GOx) 
and this time the particles were dispersed in phosphate buffer (10 mM, pH 6.8). Subsequently, 
the activity and zeta potential were measured at pH 6.8 as shown in Table 10. 
Table 10. Zeta potential and enzymatic activity of glucose oxidase immobilized- gold NPs of 
d≈50 nm. 
Sample Description Zeta potential (mV) (n=3) 
Enzymatic activity 
(U/g of enzyme) 
(n=3) 
1 
Gold NPs-enzyme (in phosphate 10mM, pH 5.8)  
Immobilization conditions: 
 0.46 mg of gold NPs 
 Normal reaction conditions 
-4.0±0.9 (11.2±0.3)×102 
2 
Gold NPs-enzyme (in phosphate 10mM, pH 6.8)  
Immobilization conditions: 
 0.46 mg of gold NPs 
 Normal reaction conditions 
-25.4±0.2 (25.7±0.7)×102 
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The results, given in show that the zeta potential has increased by increasing pH to 6.8. In 
addition, the enzymatic activity is also nearly doubled comparing to pH 5.8. In fact, this 
observation supports the that the enzymatic activity decreases by increasing the chance of 
aggregation of NPs. It should also be noted that that the enzymatic activity itself is pH 
dependent. The optimum pH for GOx is 5.5 and by increasing the pH to 6.8 the enzymatic 
activity decreases about 10 % of the maximum activity69. However, apparently avoiding the 
aggregation is much more effective in increasing the enzymatic activity. But in a larger 
viewpoint, the immobilization of GOx on gold NPs under these conditions results in a significant 
decrease in enzymatic activity which is unfavorable for our application of encapsulation 
purposes. As mentioned earlier, since the previous studies have shown a better thermostability 
and shelf life of immobilized enzyme on gold NPs, the encapsulation of such a combination is 
subject to a debate, whether the increased thermostability will compensate the significant losses 
in enzymatic activity or not. 
5.6. Summary 
To conclude this section, the immobilization of GOx on gold NPs, although successful, 
did not provide the expected increase in activity. While it may help to increase the 
thermostability and shelf life of GOx, the immobilization on NPs will need to be improved to 
achieve high enzymatic activity before these enzyme immobilized-gold NPs can be applied to 
the encapsulation process. After the immobilization of GOx on gold NPs, the results of 
enzymatic activity measurements showed a decrease in enzymatic activity of GOx due to two 
main reasons. First the possible conformation change of the enzyme and second the coalescence 
of the gold NPs in which the enzyme acted as a chemical glue to aggregate the gold NPs. The 
latter’s effect is more significant once the immobilization of the enzyme is done on gold NPs 
with a size close to the size of GOx itself.  
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The present research aimed at investigating the possibility of GOx encapsulation and the 
immobilization of antibodies on the outer surface of alginate microcapsules to construct an 
antibacterial platform for paper coating and finally for the preparation of bioactive paper in 
larger scales which has the ability to capture the pathogens and to deactivate them using the 
chemical anti-pathogenic agent, hydrogen peroxidase, produced inside microcapsules by GOx 
activity. 
Throughout this study it has been demonstrated that GOx can be encapsulated in alginate 
microcapsules using the vibrational break up of laminar flow encapsulation technique and 
stabilization of microcapsules in a calcium chloride bath presenting the encapsulation efficiency 
of 47 % while maintaining some of the enzymatic activity. These microcapsules have an average 
diameter of 120±20 µm and their size distribution was obtained using traditional optical 
microscope. Since the surface of alginate microcapsules does not contain a significantly 
chemically active group, they could easily be covered with another layer composed of chitosan 
using the ionotropic affinity between these two polymers. Chitosan contains amino groups 
which can be used for further modifications. This successful coverage was monitored by 
elemental analysis which showed the presence of nitrogen in the structure of microcapsules that 
can only be found in the structure of chitosan since alginate does not contain nitrogen. Also 
chitosan coverage was observable by using FITC-labeled chitosan that produced a fluorescent 
signal in laser scanning microscopy. Human IgG was chosen as a model antibody to check the 
possibility of immobilization of antibodies on the outer surface of microcapsules using the 
glutaraldehyde coupling reaction. To demonstrate the successful immobilization, MALDI-TOF-
MS was used and the superimposition of two distinctive peaks of the antibody with the broad 
peak resulting from the polysaccharide structure of microcapsules was observable showing the 
covalent immobilization of human IgG on microcapsules. To measure the enzymatic activity of 
our designed platform, oxygen electroanalysis was used after the enzyme encapsulation and also 
after each modification step. Although the results show a decrease in enzymatic activity 
especially after encapsulation of GOx, we were able to maintain some of its activity showing 
that our approach has been successful to prepare the desired immobilization platform and we 
expect it to be adaptable to various enzyme-antibody combinations. 
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To verify the antibacterial properties of our designed platform, E. coli K-12 was chosen 
as a model pathogen. Preliminary observation of bacterial growth inhibition was made by its 
cultivation in LB broth culture media in a petri dish and the emergence of transparent halo 
around the central spot where the microcapsules were placed depicted successful bacterial 
growth inhibition. The detail of this bacterial growth inhibition was studied using optical density 
measurements of the culture media at different time points in order to determine a threshold of 
enzymatic activity with which we are able to inhibit bacterial growth. This threshold was found 
to be 1.3×10-2 U/ml for E. coli K-12 growth inhibition of 6.7×108 cells/ml. Similarly, the 
minimum initial amount of bacteria that could grow at an enzymatic activity equal to 1.9×10-2 
U/ml was found to be 6.7×108 cells/ml. At this enzymatic activity threshold, the behavior of 
antibacterial microcapsules was also compared to the behavior of free GOx. The immobilization 
of GOx on gold NPs did not show a significant enhancement and instead, a decrease in 
enzymatic activity.  
For the future work of this study, since we already demonstrated that human IgG can be 
immobilized on our microcapsules, some quantitative analysis is be required to determine the 
immobilization efficiency. Also it may be needed to immobilize a specific antibody which has 
an affinity for a specific pathogen in order to check if the antibody stays active after 
immobilization so that we can possibly observe the efficiency of the system in capturing and 
deactivation of the pathogen. Moreover, since so far we checked and monitored the antibacterial 
properties of the microcapsules during a period of 24 hours, it is suggested that complementary 
studies be done to monitor this characteristic over a larger time windows (i.e. ranging from a 
few weeks to a few months). Finally, these antibacterial microcapsules are to be introduced to  
the laboratorial paper coating process in order to check the efficiency of the system once it is 
coated on paper. This process can be done using a cylindrical laboratory coater (Figure 43) as 
previously performed in Dr. Rochefort’s research group for a combination of the enzyme laccase 
encapsulated in poly(ethyleneimine) microcapsules79. In the related study, it was demonstrated 
that the encapsulated enzyme maintains its activity once the microcapsules are coated on paper 
surface. Therefore, we expect that our hydrogen peroxide producing microcapsules, once 
modified with antibodies could be used to make an efficient bioactive paper with antibacterial 
properties at large scales. 
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Figure 43. Cylindrical laboratory coater -CLC 7000 (reproduced from reference 79). 
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